

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Chronic dysglycemia in critically ill patients with Covid-19 – a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-071330
Article Type:	Original research
Date Submitted by the Author:	23-Dec-2022
Complete List of Authors:	<p>Balintescu, Anca; Karolinska Institute, Department of Clinical Science and Education, Södersjukhuset Rysz, Susanne; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Hertz, Carl; Stockholm South General Hospital Anaesthesia Department ICU Grip, Jonathan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Cronhjort, Maria; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Oldner, Anders; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Svensen, Christer; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Mårtensson, Johan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care</p>
Keywords:	Adult intensive & critical care < ANAESTHETICS, COVID-19, DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Chronic dysglycemia in critically ill patients with Covid-19 – a retrospective cohort study

Anca Balintescu, MD^{1, 2}; Susanne Rysz, MD^{3, 4}; Carl Hertz, MD²; Jonathan Grip, MD, PhD^{3, 5}; Maria Cronhjort, MD, PhD^{1, 2}; Anders Oldner MD, PhD^{3, 6}; Christer Svensen MD, PhD^{1, 2}; Johan Mårtensson, MD, PhD^{3, 6}

¹ Department of Clinical Science and Education Karolinska Institute, Unit of Anesthesiology and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

² Department of Anesthesia and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

³ Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Norrbacka S2:05, SE-17176 Stockholm, Sweden

⁴ Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden

⁵ Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden

⁶ Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Norrbacka S2:05, SE-17176 Stockholm, Sweden

Corresponding Author:

Anca Balintescu, ANOPIVA, Södersjukhuset, Sjukhusbacken 10, 11883 Stockholm, Sweden. Phone: +46 (0)722 7023 83. Fax: +46 (0)8-616 22 08. Email: anca.balintescu@ki.se

Keywords: HbA1c, ICU, Covid-19, prevalence, glycemic control, diabetes

Abstract

Objective: Using glycated hemoglobin A1c (HbA1c) screening, we aimed to determine the prevalence of chronic dysglycemia (prediabetes or diabetes) among patients with Covid-19 admitted to the intensive care unit (ICU). Additionally, we aimed to explore the association between chronic dysglycemia and clinical outcomes related to ICU stay.

Design: Multicenter prospective observational study

Setting: ICUs in three hospitals in Stockholm, Sweden

Participants: Covid-19 patients admitted to the ICU between 5 March and 13 August 2020 with available HbA1c at admission. Chronic dysglycemia was determined based on previous history of diabetes and HbA1c.

Primary and secondary outcomes measures: Primary outcome was the actual prevalence of chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among Covid-19 patients. Secondary outcome was the association of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive mechanical ventilation (IMV), and renal replacement therapy (RRT) use, accounting for treatment selection bias.

Results: A total of 308 patients with available admission HbA1c were included. Chronic dysglycemia prevalence assessment was restricted to 206 patients admitted to three ICUs in which HbA1c was measured on all admitted patients. Chronic dysglycemia was present in 82.0% (95% CI 76.1%-87.0%) of patients, with prediabetes present in 40.2% (95% CI 33.5%-47.3%), unknown diabetes in 20.9% (95% CI 15.5%-27.1%), well-controlled diabetes in 7.8% (95% CI 4.5%-12.3%), and uncontrolled diabetes in 13.1% (95% CI 8.8%-18.5%). All patients with available HbA1c were included for the analysis of the relationship between chronic

dysglycemia and secondary outcomes. We found no independent association between chronic dysglycemia and 90-day mortality, ICU length of stay, duration of IMV or RRT use. Risk estimates remained virtually unchanged after excluding patients with specific treatment limitations.

Conclusions: In our cohort of critically ill Covid-19 patients, the prevalence of chronic dysglycemia was 82%. We found no association between chronic dysglycemia and clinical outcomes.

Strengths and limitations of this study

- Presents prevalence of chronic dysglycemia in an ICU population with Covid-19 based on additional quantification of admission HbA1c
- Actual prevalence of chronic dysglycemia calculation in all ICU admitted patients, reducing the risk of ascertainment bias
- Treatment limitations were considered in the analysis of clinical outcomes, thereby reducing the risk of treatment selection bias.
- We lack data on glycemetic control during ICU stay, that might have influenced clinical outcomes

Background

Diabetes has been identified as a frequent comorbidity in patients with Covid-19, with a prevalence ranging from 7.4% to 34.3% among those requiring hospitalization [1-3]. A meta-analysis published in April 2020 found diabetes to be the second most

1
2
3 frequent comorbidity in patients with Covid-19 admitted to the intensive care unit
4
5 (ICU) [4]. Furthermore, Covid-19 patients with diabetes appear to have a significantly
6
7 higher risk of ICU admission and worse prognosis than Covid-19 patients without
8
9 diabetes [4-6]. Particularly, a glycated hemoglobin A1c (HbA1c) level above 7% (53
10
11 mmol/mol) was identified as risk factor for ICU admission [7].
12
13

14
15 Recent data also indicates that diabetes is associated with worse prognosis among
16
17 ICU patients with Covid-19 [8]. However, these studies did not include HbA1c
18
19 measurements to identify patients with prediabetes or previously undiagnosed
20
21 diabetes. This is an important limitation since both prediabetes and diabetes is
22
23 considerably under-diagnosed both in the community [9] and in the ICU [10].
24
25

26
27 Additionally, a history of diabetes diagnosis and HbA1c at ICU admission, measured
28
29 in consecutively admitted patients, is important in determining the true prevalence of
30
31 chronic dysglycemia in the critically ill Covid-19 population. Finally, information about
32
33 limitations of life-sustaining treatment were not considered in previous outcome
34
35 analyses. This is unfortunate since the presence of such limitations may introduce
36
37 treatment selection bias.
38
39

40
41 We therefore conducted a multicenter observational study using quantification of
42
43 HbA1c and information about diabetes history to determine the actual prevalence of
44
45 chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among
46
47 Covid-19 patients admitted to ICU. In addition, we aimed to explore the relationship
48
49 of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive
50
51 mechanical ventilation (IMV) and severe acute kidney injury requiring renal
52
53 replacement therapy (RRT) accounting for treatment selection bias. We hypothesised
54
55 that prevalence of chronic dysglycemia in Covid-19 patients admitted to the ICU
56
57 exceeds the prevalence of chronic dysglycemia in the non Covid-19 critically ill
58
59
60

1
2
3 population. Moreover, we hypothesised that such chronic dysglycemia would be
4
5 associated with worse clinical outcomes during ICU stay in patients with Covid-19.
6
7
8
9

10 11 12 **Material and Methods**

13
14 The study was approved by the Swedish Ethical Review Authority (approval number
15
16 2020-01302, amendment 2020-02890) with a waiver of informed consent. The study
17
18 was performed in accordance with the Helsinki Declaration and reported in
19
20 conformity with the STROBE statement [11]
21
22

23
24 Patient and Public Involvement statement: The study is based on data that was
25
26 collected during the ongoing Covid-19 pandemic in a quality register. No intervention
27
28 was applied to the individual patient. The public and patients were not involved in the
29
30 design of the study. Results are to be disseminated to the public and scientific
31
32 community through publication in peer-reviewed journal with open access.
33
34
35
36
37

38 *Study design*

39
40 We conducted a multicenter, prospective observational study of adult (≥ 18 years)
41
42 patients with a positive polymerase chain reaction (PCR) for severe acute respiratory
43
44 syndrome coronavirus 2 (SARS-CoV-2) admitted to ten ICUs in three hospitals in
45
46 Stockholm, Sweden between March 5th and August 13th, 2020 (first wave). We
47
48 excluded patients without HbA1c obtained on admission to the ICU, patients in the
49
50 third trimester of pregnancy and patients with a primary admission diagnosis other
51
52 than Covid-19. In patients with multiple ICU admissions, only the first admission was
53
54 considered. All included patients were assessed in the outcome analyses.
55
56
57

58
59 Assessment of chronic dysglycemia prevalence was restricted to a nested cohort of
60

1
2
3 patients from ICUs in which HbA1c measurement was included in the routine
4
5 laboratory panel performed on all consecutive admissions. In the prevalence
6
7 analysis, we therefore excluded patients with available HbA1c who were admitted to
8
9 ICUs in which HbA1c was measured only at the discretion of the treating clinicians.
10
11
12
13

14 *Data collection*

15
16 HbA1c was measured in whole blood at ICU admission using the VARIANT II
17
18 TURBO Hemoglobin Testing System analyzer (Bio-Rad Laboratories GmbH) and
19
20 was reported in mmol/mol (IFCC calibrated) and in %. HbA1c was measured as part
21
22 of routine care in three ICUs and at the discretion of the treating clinician in seven
23
24 ICUs. We collected information on demographics, comorbidity, chronic medication,
25
26 HbA1c value, mortality and decision regarding limitation of life-sustaining care from
27
28 the patients' medical records (Take Care [CompuGroup Medical, Koblenz,
29
30 Germany]). International Classification of Disease (ICD) 10 codes were used to
31
32 identify comorbidity and previous history of diabetes. Additionally, data regarding
33
34 known diabetes diagnosis was extracted manually from the patients' medical records.
35
36
37
38
39 Data on body mass index (BMI), Simplified Acute Physiology Score (SAPS) 3, ICU
40
41 length of stay, duration of IMV and RRT were collected from the ICU electronic
42
43 patient data management system Clinisoft (GE, Barrington, IL).
44
45
46
47
48

49 *Prediabetes and Diabetes definitions*

50
51 Prediabetes and diabetes were diagnosed based on two complementary methods;
52
53 level of HbA1c at admission and previous medical history of diabetes, and
54
55 categorized into five groups:
56
57

58 (1) no diabetes (HbA1c <42 mmol/mol [6.0%] and no history of diabetes)
59
60

1
2
3 (2) prediabetes (HbA1c 42-47 mmol/mol [6.0-6.4%] and no history of diabetes)

4
5 (3) unknown diabetes (HbA1c \geq 48 mmol/mol [6.9 %] and no history of diabetes)

6
7 (4) controlled diabetes (HbA1c $<$ 52 mmol/mol [6.9 %] and previous history of
8
9 diabetes)

10
11 (5) uncontrolled diabetes (HbA1c \geq 52 mmol/mol [6.9 %] and previous history of
12
13 diabetes).

14
15 Cut off values for HbA1c according to the World Health Organization were used [12].

16
17 Individuals in group (2), (3), (4) and (5) were considered to have chronic dysglycemia
18
19 compared to those in group (1) labeled “no chronic dysglycemia”.

20 21 22 23 24 25 26 *Outcomes*

27
28 The primary outcome was the prevalence of chronic dysglycemia. Secondary
29
30 outcomes included 90-day mortality, ICU length of stay, duration of IMV, and RRT
31
32 use.

33 34 35 36 37 *Statistical Analysis*

38
39 We analyzed data using STATA version 12.1 (Stata Corp., College Station, Texas).
40
41 Categorical data is presented as numbers and percentages and compared using the
42
43 chi-square test or Fisher's exact test. Continuous data is summarized as median with
44
45 interquartile range (IQR) and compared using the Mann-Whitney U test (for two
46
47 groups) or the Kruskal Wallis test (for multiple groups). The prevalence of chronic
48
49 dysglycemia (primary outcome) was presented as percentages with 95% confidence
50
51 intervals (CI). We displayed time to death within 90 days using Kaplan-Meier curves.
52
53 Survival curves were compared using a log-rank test. We used multivariable Cox
54
55 regression analysis to assess the association between chronic dysglycemia and 90-
56
57
58
59
60

day mortality. We used multivariable linear regression analysis to assess the association with ICU length of stay and duration of IMV. Both these outcomes were found to be well approximated by log-normal distributions and were therefore log-transformed before analysis with results presented as geometric means (95% CI). We used multivariable logistic regression analysis to assess the association with RRT use, before and after excluding patients with RRT as a treatment limitation. All regression models were adjusted for the following predetermined confounders: SAPS 3, age and sex. A two-sided P-value <0.05 was considered statistically significant.

Results

Patients

A total of 584 patients with positive SARS-CoV-2 test were admitted to the study ICUs during the study period. We excluded 225 patients without available HbA1c, six pregnant patients, 16 readmissions and 29 patients without symptoms associated with Covid-19. Therefore, we included 308 patients with available HbA1c for outcome analysis. Among those 308 patients, 206 consequently admitted patients in which HbA1c was included in the admission routine laboratory panel were used for prevalence calculation (Figure 1). Baseline characteristics and treatment limitations of the entire study population are detailed in Table 1.

Table 1. Baseline characteristics and treatment limitations

Characteristic	Chronic dysglycemia					P ^e
	No chronic dysglycemia	Prediabetes	Unknown diabetes	Controlled diabetes	Uncontrolled diabetes	
No. (%)	61 (19.8)	114 (37.0)	60 (19.4)	25 (8.11)	48 (15.5)	
Age, years	57 (51,63)	61 (53, 68)	60 (52, 68)	63 (57, 71)	62 (55,69)	0.02
Male sex	48 (78.6)	92 (80.7)	47 (78.3)	21 (84.0)	36 (75.0)	0.90
Body mass index ^a , kg/m ²	27 (25, 32)	27 (25, 30)	28 (25, 31)	29 (26, 32)	30 (26, 33)	0.97
HbA1c, mmol/mol	39 (36, 40)	44 (43, 46)	51 (49, 57)	47 (44, 49)	70 (61, 81)	<0.001
Diabetes treatment						
Diet only				6 (24.0)	2 (4.1)	
OAD only				17 (68)	19 (39.5)	

Insulin only				1 (4.0)	12 (25.0)	
OAD+Insulin				1 (4.0)	15 (31.2)	
Comorbidity						
Hypertension	18 (29.5)	40 (35.0)	23 (38.3)	16 (64.0)	34 (70.8)	0.02
Heart failure	6 (9.8)	5 (4.3)	6 (10.0)	0 (0.0)	3 (6.2)	0.24
Previous myocardial infarction	2 (3.2)	4 (3.5)	6 (10.0)	0 (0.0)	7 (14.5)	0.38
Chronic kidney disease	4 (6.5)	13 (11.4)	7 (11.6)	6 (24.0)	11 (22.9)	0.09
Liver disease	2 (3.2)	4 (3.5)	1 (1.6)	1 (4.0)	1 (2.0)	1.00
Any malignancy	0 (0.0)	8 (7.0)	2 (3.3)	2 (8.0)	4 (8.3)	0.04
Astma/COPD	13 (21.3)	20 (17.5)	14 (23.3)	5 (20.0)	9 (18.7)	0.72
SAPS 3 ^b	53 (48, 60)	55 (49, 60)	57 (52, 62)	59 (52, 63)	56 (52, 69)	0.18
Chronic drug use						
Corticosteroids ^c	5 (8.20)	16 (14.04)	8 (13.3)	4 (16.0)	6 (12.5)	0.24
Immunosuppressive therapy ^d	1 (1.6)	8 (7.0)	3 (5.0)	1 (4.0)	1(2.0)	0.31
Treatment limitations ^f						
Any limitation	14 (22.9)	19 (16.6)	13 (21.6)	8 (32.0)	13 (27.0)	0.80
No RRT	5 (8.2)	7 (6.1)	5 (8.3)	5 (20.0)	6 (12.5)	0.78
No IMV	6 (9.8)	10 (8.7)	4 (6.6)	4 (16.0)	6 (12.5)	0.97
No CPR	9 (14.7)	19 (16.6)	12 (20.0)	8 (32.0)	12 (25.0)	0.29
No ECMO	7 (11.4)	3 (2.6)	5 (8.3)	3 (12.0)	3 (6.2)	0.10
Palliative care ^g	1 (1.6)	18 (16.5)	7 (12.2)	4 (16.6)	5 (10.8)	0.03

Data are n (%) or median (interquartile range)

HbA1c, glycated hemoglobin A1c; OAD, oral hypoglycemic agent; COPD, Chronic obstructive pulmonary disease; SAPS, Simplified Acute Physiology Score, 2 missing values (306 patients with data); RRT, renal replacement therapy; IMV, invasive mechanical ventilation; CPR, cardiopulmonary resuscitation

^aMissing data in 15 patients (293 patients with data)

^bMissing data in 2 patients (306 patients with data)

^cSystemic or inhaled corticosteroids

^dImmunosuppressive therapy was defined as: treatment with Metotrexate, Azathioprin, Ciklosporin, Tracolimus, Infliximab

^eP values for the comparison between no chronic dysglycemia and chronic dysglycemia

^fDecision taken any time during ICU stay

^gDecision to go over to palliative care taken during ICU stay

Patients with chronic dysglycemia were older, were more likely to have hypertension, malignancy and/or chronic kidney disease, and had higher SAPS 3 than patients without chronic dysglycemia. Overall, 14 (22.9%) patients in the no chronic dysglycemia group and 53 (21.5%) patients in the chronic dysglycemia group received one or more limitations of life-supporting therapies during their ICU stay. “No Cardiopulmonary resuscitation (CPR)” was the most common treatment limitation. We observed the highest proportion of limitations among patients with known (controlled or uncontrolled) diabetes. Decision to switch to palliative care was made in 1 (1.6%) patient in the no chronic dysglycemia group and 34 (13.8%) patients in the chronic dysglycemia group (P=0.03). Cumulative percentage of treatment limitations relative ICU admission is displayed in Figures S1-S4.

Primary outcome

In the nested cohort of 206 consecutive patients with available HbA1c, 169 (82.0%; 95% CI 76.1%-87.0%) were diagnosed with chronic dysglycemia. Prediabetes was present in 83 (40.2%, 95% CI 33.5%-47.3%), unknown diabetes in 43 (20.9%, 95% CI 15.5%-27.1%), well-controlled diabetes in 16 (7.8%, 95% CI 4.5%-12.3%), and uncontrolled diabetes in 27 (13.1%, 95% CI 8.8%-18.5%) patients (Figure 2).

Secondary outcomes

Nine (14.7%) patients in the no chronic dysglycemia group and 62 (25.1%) patients in the chronic dysglycemia group died within 90 days ($P=0.08$) (Table 2, Figure 3 and Figure S5). ICU length of stay and duration of IMV were similar in the two groups. IMV was delivered to 42 (68.8%) patients without chronic dysglycemia and to 187 (75.7%) patients with chronic dysglycemia ($P=0.27$). RRT was delivered to 17 (27.9%) no chronic dysglycemia patients and 42 (17.0%) chronic dysglycemia patients ($P=0.06$) (Table 2 and Table 3).

Table 2. Secondary outcomes

Outcomes	Chronic dysglycemia					P ^a
	No chronic dysglycemia (n = 61)	Prediabetes (n = 114)	Unknown diabetes (n = 60)	Controlled diabetes (n = 25)	Uncontrolled diabetes (n = 48)	
90-day mortality, n (%)	9 (14.7)	28 (24.5)	12 (20.0)	7 (28.0)	15 (31.2)	0.08
ICU length of stay, days	9 (4, 25)	14 (6, 24)	13 (6, 28)	8 (5, 21)	11 (7, 22)	0.69
Invasive mechanical ventilation, days	16 (8, 29)	14 (10, 23)	15 (10, 27)	15 (6, 21)	14 (9, 22)	0.60
Renal replacement therapy, n (%)	17 (27.9)	22 (19.3)	11 (18.3)	1 (4.0)	8 (16.6)	0.06

Data are n (%) or median (interquartile range)

ICU lengths of stay (4 missing values because of transfer to other hospital)

^aP values for the comparison between no chronic dysglycemia and chronic dysglycemia

Table 3. Multivariable regression analyses showing the association of chronic dysglycemia (versus no chronic dysglycemia) with secondary outcomes

Outcome measure	No Chronic Dysglycemia	Chronic Dysglycemia	Adjusted Risk Estimate (95% CI) ^a	Statistical test	P Value
90-day mortality, n (%)	9/61 (14.7)	62/247 (25.1)	1.61 (0.79 to 3.26)	Cox regression	0.18
ICU length of stay, days					
All patients	9 (4, 25)	13 (6, 23)	1.06 (0.78 to 1.43)	Linear regression	0.70
ICU survivors ^b	9 (5, 27)	14 (7, 24)	1.04 (0.76 to 1.43)	Linear regression	0.75
Invasive mechanical ventilation duration, days					
All patients ^c	16 (8, 29)	14 (10, 23)	0.92 (0.68 to 1.23)	Linear regression	0.58
ICU survivors ^d	16 (8, 30)	15 (10, 23)	0.93 (0.70 to 1.23)	Linear regression	0.61
Renal replacement therapy, n (%)					
All patients	17/61 (27.9)	42/247 (17.0)	0.52 (0.26 to 1.02)	Logistic regression	0.06
Patients without treatment limitation as no RRT	17/57 (29.8)	42/224 (18.8)	0.52 (0.26 to 1.04)	Logistic regression	0.10

^aMultivariable models were adjusted for Simplified Acute Physiology Score (SAPS) 3, age and sex.

^bICU length of stay in ICU survivors, 260 observations

^cInvasive mechanical ventilation duration, 227 observations

^dInvasive mechanical ventilation duration in ICU survivors, 189 observations

On multivariable regression analysis we observed a trend towards higher mortality (adjusted HR 1.61, 95% CI 0.79-3.26, P=0.18) and lower RRT use (adjusted OR 0.52, 95% CI 0.26-1.02, P=0.06) in patients with chronic dysglycemia (Table 3). The association with RRT use remained virtually unchanged after exclusion of patients with “No RRT” as treatment limitation.

Discussions

Key findings

We performed a multicenter observational investigation to determine the prevalence of chronic dysglycemia and its impact on clinical outcomes among Covid-19 patients admitted to ICU. Using available information about the patients’ diabetic status in combination with routine HbA1c assessment, we found that 82% had chronic

1
2
3 dysglycemia with two thirds having either prediabetes or undiagnosed diabetes. We
4
5 observed a trend towards increased 90-day mortality in patients with chronic
6
7 dysglycemia, with the highest mortality (31%) observed among those with
8
9 uncontrolled diabetes. Conversely, the proportion of patients receiving RRT was
10
11 lower among patients with chronic dysglycemia even when patients without “No RRT”
12
13 as treatment limitation were considered separately. We found no association of
14
15 chronic dysglycemia with ICU length of stay or duration of IMV.
16
17
18
19
20

21 *Relationship with previous studies*

22
23 A global meta-analysis of more than 16000 ICU patients with Covid-19 suggests a
24
25 pooled prevalence of known diabetes between 23-31% [13], close to the observed
26
27 prevalence in our study (21%). However, few studies have used additional HbA1c
28
29 measurements to assess the actual prevalence of chronic dysglycemia, including
30
31 prediabetes and undiagnosed diabetes. One such ICU study from Austria found a
32
33 prevalence of chronic dysglycemia of 85%, which is in close agreement with our
34
35 findings [14]. However, the Austrian study did not assess consecutive patients and
36
37 may therefore be prone to selection bias.
38
39
40

41
42 Our findings indicate that chronic dysglycemia is more common in Covid-19 patients
43
44 than in ICU patients with other admission diagnoses. In fact, in a pre-Covid-19 cohort
45
46 of general ICU patients we found a corresponding dysglycemia prevalence of 33%
47
48 [10]. The relationship between severe SARS-CoV-2 infection and dysglycemia has
49
50 different potential explanations. SARS-CoV-2 enters cells in various organs, including
51
52 the pancreas, via angiotensin-converting enzyme II (ACE2). As ACE2 is involved in
53
54 regulating pancreatic beta-cell function, a link between SARS-CoV-2 infection and
55
56 beta-cell dysfunction and diabetes development has been suggested [15].
57
58
59
60

1
2
3 Interestingly, the prevalence of elevated HbA1c below the diabetes diagnostic
4 threshold (prediabetes) was markedly higher in our Covid-19 cohort than in our
5 previous pre-Covid-19 cohort (40% vs 9%). It is possible that the duration of Covid-
6 19 symptoms before ICU admission (typically ten days in the literature [16]) was
7 sufficient to trigger new onset hyperglycemia with mildly elevated HbA1c.
8
9

10
11 In addition to the above speculations about SARS-CoV-2 as a *cause* of dysglycemia,
12 there is also evidence suggesting that patients with preexisting dysglycemia are
13 prone to a more severe course of Covid-19. For example, some studies have shown
14 that hospitalized SARS-CoV-2 positive with prediabetes, unknown diabetes, and
15 known poorly controlled diabetes are at increased risk of SARS-CoV-2 associated
16 respiratory failure requiring intensive care [17]. A higher burden of comorbidities,
17 hyperglycemia *per se*, and chronic low-grade inflammation in diabetes may explain
18 this observation[18].
19
20
21
22
23
24
25
26
27
28
29
30
31

32
33 Whether chronic dysglycemia is associated with worse outcomes among Covid-19
34 patients admitted to ICU remains uncertain. A multicenter study from France
35 including 410 ICU patients with Covid-19, found no association between the severity
36 of dysglycemia and tracheal intubation and/or death within 7 days of admission in
37 patients with diabetes than in those without diabetes [19]. This is in accordance with
38 the findings of our study. In contrast, others found higher mortality in the subgroup of
39 mechanically ventilated patients with diabetes [14].
40
41
42
43
44
45
46
47
48

49 We previously demonstrated an independent association between chronic
50 dysglycemia and need for RRT in critically ill non-Covid-19 patients [10]. This
51 association was, however, not found in the present study. In fact, we observed a
52 higher proportion of patients requiring RRT among our patients without chronic
53 dysglycemia. Exclusion of patients “not for RRT”, did not substantially alter this
54
55
56
57
58
59
60

1
2
3 finding. Importantly, limitations in life-sustaining care were more common in the
4
5 known diabetes groups (well controlled and uncontrolled diabetes) than in all other
6
7 groups. We cannot exclude the possibility that patients with severe acute or chronic
8
9 kidney injury did not reach the ICU because of treatment limitation decisions made at
10
11 hospital arrival or on the medical ward. This might have influenced the number of
12
13 patients with kidney injury reaching the ICU, affecting predominantly patients with
14
15 chronic dysglycemia, as they are usually older and have multiple comorbidities.
16
17
18
19
20

21 *Strengths and limitations*

22
23 Our study has several strengths. It is the first to assess the prevalence of chronic
24
25 dysglycemia in an ICU population with Covid-19 based on additional quantification of
26
27 admission HbA1c. This approach reduced bias due to events that would have
28
29 influenced HbA1c values obtained before ICU admission. Additionally, we restricted
30
31 the prevalence assessment to a cohort of patients who were admitted to ICUs where
32
33 HbA1c was part of the routine laboratory panel, thereby reducing the risk of
34
35 ascertainment bias. Furthermore, we considered treatment limitations in our analysis
36
37 of clinical outcomes, thereby reducing the risk of treatment selection bias. Finally, we
38
39 included patients admitted to ten ICUs in three University hospitals, thus providing a
40
41 degree of external validity for applying our findings to similar settings.
42
43
44
45

46 Our study has limitations. We lack data on conditions and treatment that might have
47
48 influenced admission HbA1c, such as haemoglobinopathies and blood transfusion
49
50 before ICU admission. In addition, we lack information about glycemic control during
51
52 intensive care, which might have modified clinical outcomes.
53
54
55
56
57

58 **Conclusion**

1
2
3 In our multicenter cohort of Covid-19 patients admitted to the ICU, HbA1c screening
4 diagnosed chronic dysglycemia in four out of five patients with the majority having
5
6 diagnosed chronic dysglycemia in four out of five patients with the majority having
7
8 either prediabetes or previously undiagnosed diabetes. Chronic dysglycemia was not
9
10 significantly associated with mortality, ICU length of stay, duration of invasive
11
12 mechanical ventilation or renal replacement therapy use. These findings indicate that
13
14 chronic dysglycemia may be a risk factor for severe Covid-19. However, Covid-19
15
16 prognosis in the ICU does not appear to be modified by chronic dysglycemia.
17
18
19
20

21 **Acknowledgments**

22
23 **Author Contributions:** Anca Balintescu, Johan Mårtensson, Maria Cronhjort,
24
25 Christer Svensen, Anders Oldner, Jonathan Grip: Conceptualization, Methodology,
26
27 Software, reviewing and Editing
28

29
30 Anca Balintescu, Susanne Rysz, Carl Hertz: Data curation

31
32 Anca Balintescu, Johan Mårtensson: Writing- Original draft preparation.

33
34
35 **Funding** A.B. and J.M. were supported by Region Stockholm (clinical research
36
37 appointment and ALF project grants), grant number 580282.
38

39
40 A non-peer-reviewed version of this article has been a part of a publicly defended
41
42 PhD thesis ISBN 978-91-8016-719-2 and was submitted to Karolinska Institute Open
43
44 Archive, available at <https://openarchive.ki.se/xmlui/handle/10616/48203> on 19
45
46 [September 2022](#).
47
48

49
50 **Competing interest:** The authors have no competing interest relevant to this work.

51
52 **Data availability:** The data that support the findings of this study are available from
53
54 the corresponding author upon reasonable request.
55

56
57
58 **Ethics Approval Statement:** The study was approved by the Swedish Ethical
59
60 Review Authority (approval number 2020-01302).

References

- [1] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases* 2020;94:91-5. doi:10.1016/j.ijid.2020.03.017
- [2] Liu Y, Lu R, Wang J, Cheng Q, Zhang R, Zhang S, et al. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. *BMC Endocrine Disorders* 2021;21(1):1-10. doi:10.1186/s12902-021-00717-6
- [3] Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal* 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
- [4] Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol* 2020;127:104354. doi:10.1016/j.jcv.2020.104354
- [5] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020;395. doi:10.1016/S0140-6736(20)30566-3
- [6] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/metabolism research and reviews* 2020:e3319 doi: 10.1002/dmrr.3319.
- [7] Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J, et al. Clinical Features and Risk Factors of ICU Admission for COVID-19 Patients with Diabetes. *Journal of Diabetes Research* 2020:5237840. doi:10.1155/2020/5237840
- [8] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA internal medicine* 2020;180(10):1345-55. doi:10.1001/jamainternmed.2020.3539
- [9] Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. *Diabetes Research and Clinical Practice* 2014;103(2):150-60. doi:10.1016/j.diabres.2013.11.001
- [10] Balintescu A, Palmgren I, Lipcsey M, Oldner A, Larsson A, Cronhjort M, et al. Prevalence and impact of chronic dysglycemia in intensive care unit patients-A retrospective cohort study. *Acta Anaesthesiol Scand* 2021;65(1):82-91. doi:10.1111/aas.13695
- [11] Erik von Elm DGA, Matthias Egger, Stuart J. Pocock, Peter C. Gøtzsche, and Jan P. Vandembroucke. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. *Annals of Internal Medicine* 2007;147(8):573-7. doi:10.7326/0003-4819-147-8-200710160-00010 %m 17938396
- [12] Organisation WH. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus, [https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-\(-hba1c\)-in-diagnosis-of-diabetes-mellitus](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(-hba1c)-in-diagnosis-of-diabetes-mellitus); [accessed 07 February 2022].
- [13] Tan E, Song J, Deane AM, Plummer MP. Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis. *Chest* 2021;159(2):524-36. doi:10.1016/j.chest.2020.10.014
- [14] Klein SJ, Mayerhöfer T, Fries D, Preuß Hernández C, Joannidis M, Collaborators, et al. Elevated HbA1c remains a predominant finding in severe COVID-19 and may be associated with increased mortality in patients requiring mechanical ventilation. *Critical Care* 2021;25(1):1-4. doi:10.1186/s13054-021-03730-2

- 1
2
3 [15] Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for
4 relationship between SARS-CoV-2 and diabetes. *Acta Physiologica* 2021;233(4):1-13.
5 doi:10.1111/apha.13733
6
7 [16] Larsson E, Brattstrom O, Agvald-Ohman C, Grip J, Jalde FC, Stralin K, et al.
8 Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary
9 hospital in Stockholm, Sweden. *Acta anaesthesiologica Scandinavica* 2021;65(1):76-
10 81. doi:10.1111/aas.13694
11
12 [17] Rysz S, Jonsson Fagerlund M, Rimes-Stigare C, Larsson E, Campoccia Jalde F,
13 Mårtensson J. Chronic dysglycemia and risk of SARS-CoV-2 associated respiratory
14 failure in hospitalized patients. *Acta anaesthesiologica Scandinavica* 2022;66(1):48-
15 55. doi:10.1136/bjsports-2021-104080.;
16
17 [18] Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the
18 Interrelationship and Risks for a Severe Course. *Frontiers in endocrinology*
19 2021;12:649525. doi:10.3389/fendo.2021.649525
20
21 [19] Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic
22 characteristics and prognosis of inpatients with COVID-19 and diabetes: the
23 CORONADO study. *Diabetologia* 2020;63(8):1500-15. doi:10.1007/s00125-020-
24 05180-x
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 **Figure legends**

4 **Figure 1.** Flow chart of study population

5
6 **Figure 2.** Prevalence of prediabetes, unknown diabetes and known diabetes among 206
7 consecutive ICU patients with Covid-19

8
9 **Figure 3.** Probability of survival in no chronic dysglycemia patients and in patients with
10 chronic dysglycemi
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Prevalence of prediabetes, unknown diabetes and known diabetes among 206 consecutive ICU patients with Covid-19

144x102mm (144 x 144 DPI)




Figure 3. Probability of survival in no chronic dysglycemia patients and in patients with chronic dysglycemi

770x521mm (144 x 144 DPI)




Figure S1. Cumulative percentage of patients with a treatment limitation: no renal replacement therapy. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S2. Cumulative percentage of patients with a treatment limitation: no cardiopulmonary resuscitation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S3. Cumulative percentage of patients with a treatment limitation: no invasive mechanical ventilation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S4. Cumulative percentage of patients with a treatment limitation: no extracorporeal membrane oxygenation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S5. Probability of survival in the study groups

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Page references for document: **Chronic dysglycemia in critically ill patients with Covid-19 – a retrospective cohort study**

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods⁴			
Study design	4	Present key elements of study design early in the paper	4, 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5-7 NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5-6, Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 8 NA NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8-9, Figure 1 Figure 1 Figure 1

1	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
2				Table
3				1
4			(b) Indicate number of participants with missing data for each variable of interest	Table
5				1
6			(c) Summarise follow-up time (eg, average and total amount)	NA
7				
8	Outcome data	15*	Report numbers of outcome events or summary measures over time	10-11
9				Table
10				2-3

For peer review only

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 2 3 4 5 6 7 8	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10-11 Table 3
9 10 11 12	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11 Figure 2,3,S1- 4, S5
13	Discussion			
14	Key results	18	Summarise key results with reference to study objectives	11
15 16 17	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
18 19 20 21	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
22	Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
23	Other information			
24 25 26	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Prevalence and impact of chronic dysglycemia among patients with Covid-19 in Swedish intensive care units: a multicenter, retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-071330.R1
Article Type:	Original research
Date Submitted by the Author:	09-May-2023
Complete List of Authors:	Balintescu, Anca; Karolinska Institute, Department of Clinical Science and Education, Södersjukhuset Rysz, Susanne; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Hertz, Carl; Stockholm South General Hospital Anaesthesia Department ICU Grip, Jonathan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Cronhjort, Maria; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Oldner, Anders; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Svensen, Christer; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Mårtensson, Johan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Adult intensive & critical care < INTENSIVE & CRITICAL CARE, COVID-19, DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and impact of chronic dysglycemia among patients with Covid-19 in Swedish intensive care units: a multicenter, retrospective cohort study

Anca Balintescu, MD, PhD^{1, 2}; Susanne Rysz, MD^{3, 4}; Carl Hertz, MD²; Jonathan Grip, MD, PhD^{3, 5}; Maria Cronhjort, MD, PhD^{1, 2}; Anders Oldner MD, PhD^{3, 6}; Christer Svensen MD, PhD^{1, 2}; Johan Mårtensson, MD, PhD^{3, 6}

¹ Department of Clinical Science and Education Karolinska Institute, Unit of Anesthesiology and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

² Department of Anesthesia and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

³ Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Norrbacka S2:05, SE-17176 Stockholm, Sweden

⁴ Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden

⁵ Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden

⁶ Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Norrbacka S2:05, SE-17176 Stockholm, Sweden

Corresponding Author:

Anca Balintescu, ANOPIVA, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden. Phone: +46 (0)722 7023 83. Fax: +46 (0)8-616 22 08. Email: anca.balintescu@ki.se

Keywords: HbA1c, ICU, Covid-19, prevalence, glycemic control, diabetes

Abstract

Objective: Using glycated hemoglobin A1c (HbA1c) screening, we aimed to determine the prevalence of chronic dysglycemia among patients with Covid-19 admitted to the intensive care unit (ICU). Additionally, we aimed to explore the association between chronic dysglycemia and clinical outcomes related to ICU stay.

Design: Multicenter retrospective observational study

Setting: ICUs in three hospitals in Stockholm, Sweden

Participants: Covid-19 patients admitted to the ICU between 5 March and 13 August 2020 with available HbA1c at admission. Chronic dysglycemia was determined based on previous diabetes history and HbA1c.

Primary and secondary outcomes: Primary outcome was the actual prevalence of chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among Covid-19 patients. Secondary outcome was the association of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive mechanical ventilation (IMV), and renal replacement therapy (RRT), accounting for treatment selection bias.

Results: A total of 308 patients with available admission HbA1c were included. Chronic dysglycemia prevalence assessment was restricted to 206 patients admitted ICUs in which HbA1c was measured on all admitted patients. Chronic dysglycemia was present in 82.0% (95% CI 76.1%-87.0%) of patients, with prediabetes present in 40.2% (95% CI 33.5%-47.3%), unknown diabetes in 20.9% (95% CI 15.5%-27.1%), well-controlled diabetes in 7.8% (95% CI 4.5%-12.3%), and uncontrolled diabetes in 13.1% (95% CI 8.8%-18.5%). All patients with available HbA1c were included for the analysis of the relationship between chronic dysglycemia and secondary outcomes.

1
2
3 We found no independent association between chronic dysglycemia and 90-day
4 mortality, ICU length of stay, or duration of IMV. After excluding patients with specific
5 treatment limitations, no association between chronic dysglycemia and RRT use was
6 observed.
7
8
9
10

11
12 **Conclusions:** In our cohort of critically ill Covid-19 patients, the prevalence of chronic
13 dysglycemia was 82%. We found no robust associations between chronic dysglycemia
14 and clinical outcomes when accounting for treatment limitations.
15
16
17
18
19
20
21
22
23

24 **Strengths and limitations of this study**

- 25 • Presents prevalence of chronic dysglycemia in an ICU population with Covid-
26 19 based on additional quantification of admission HbA1c
- 27
28 • Actual prevalence of chronic dysglycemia calculation in all ICU admitted
29 patients, reducing the risk of ascertainment bias
- 30
31 • Treatment limitations were considered in the analysis of clinical outcomes,
32 thereby reducing the risk of treatment selection bias.
- 33
34 • We lack data on glycemetic control during ICU stay, that might have influenced
35 clinical outcomes
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Background**

51 Diabetes has been identified as a frequent comorbidity in patients with Covid-19, with
52 a prevalence ranging from 7.4% to 34.3% among those requiring hospitalization [1-
53 3]. A meta-analysis published in April 2020 found diabetes to be the second most
54 frequent comorbidity in patients with Covid-19 admitted to the intensive care unit
55
56
57
58
59
60

1
2
3 (ICU) [4]. Furthermore, Covid-19 patients with diabetes appear to have a significantly
4
5 higher risk of ICU admission and worse prognosis than Covid-19 patients without
6
7 diabetes [4-6]. Particularly, a glycated hemoglobin A1c (HbA1c) level above 7% (53
8
9 mmol/mol) was identified as risk factor for ICU admission [7].

10
11
12 Recent data also indicates that diabetes is associated with worse prognosis among
13
14 ICU patients with Covid-19 [8]. However, these studies did not include HbA1c
15
16 measurements to identify patients with prediabetes or previously undiagnosed
17
18 diabetes. This is an important limitation since both prediabetes and diabetes is
19
20 considerably under-diagnosed both in the community [9] and in the ICU [10].

21
22 Additionally, a history of diabetes diagnosis and HbA1c at ICU admission, measured
23
24 in consecutively admitted patients, is important in determining the true prevalence of
25
26 chronic dysglycemia in the critically ill Covid-19 population. Finally, information about
27
28 limitations of life-sustaining treatment were not considered in previous outcome
29
30 analyses. This is unfortunate since the presence of such limitations may introduce
31
32 treatment selection bias.

33
34
35 We therefore conducted a multicenter observational study using quantification of
36
37 HbA1c and information about diabetes history to determine the actual prevalence of
38
39 chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among
40
41 Covid-19 patients admitted to ICU. In addition, we aimed to explore the relationship
42
43 of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive
44
45 mechanical ventilation (IMV) and severe acute kidney injury requiring renal
46
47 replacement therapy (RRT) accounting for treatment selection bias. We hypothesised
48
49 that prevalence of chronic dysglycemia in Covid-19 patients admitted to the ICU
50
51 exceeds the prevalence of chronic dysglycemia in the non Covid-19 critically ill
52
53
54
55
56
57
58
59
60

1
2
3 population. Moreover, we hypothesised that such chronic dysglycemia would be
4
5 associated with worse clinical outcomes during ICU stay in patients with Covid-19.
6
7
8
9

10 11 12 **Material and Methods**

13
14 The study was approved by the Swedish Ethical Review Authority (approval number
15
16 2020-01302, amendment 2020-02890) with a waiver of informed consent. The study
17
18 was performed in accordance with the Helsinki Declaration and reported in
19
20 conformity with the STROBE statement [11]
21
22

23
24 Patient and Public Involvement statement: The study is based on data that was
25
26 collected during the ongoing Covid-19 pandemic in a quality register. No intervention
27
28 was applied to the individual patient. The public and patients were not involved in the
29
30 design of the study. Results are to be disseminated to the public and scientific
31
32 community through publication in peer-reviewed journal with open access.
33
34
35
36

37 *Study design*

38
39 We conducted a multicenter, retrospective observational study of adult (≥ 18 years)
40
41 patients with a positive polymerase chain reaction (PCR) for severe acute respiratory
42
43 syndrome coronavirus 2 (SARS-CoV-2) admitted to ten ICUs in three hospitals in
44
45 Stockholm, Sweden between March 5th and August 13th, 2020 (first wave). We
46
47 excluded patients without HbA1c obtained on admission to the ICU, patients in the
48
49 third trimester of pregnancy and patients with a primary admission diagnosis other
50
51 than Covid-19. In patients with multiple ICU admissions, only the first admission was
52
53 considered. All included patients were assessed in the outcome analyses.
54
55
56

57
58 Assessment of chronic dysglycemia prevalence was restricted to a nested cohort of
59
60

1
2
3 patients from ICUs in which HbA1c measurement was included in the routine
4
5 laboratory panel performed on all consecutive admissions. In the prevalence
6
7 analysis, we therefore excluded patients with available HbA1c who were admitted to
8
9 ICUs in which HbA1c was measured only at the discretion of the treating clinicians.
10
11
12
13

14 *Data collection*

15
16 HbA1c was measured in whole blood at ICU admission using the VARIANT II
17
18 TURBO Hemoglobin Testing System analyzer (Bio-Rad Laboratories GmbH) and
19
20 was reported in mmol/mol (IFCC calibrated) and in %. HbA1c was measured as part
21
22 of routine care in three ICUs and at the discretion of the treating clinician in seven
23
24 ICUs. We collected information on demographics, comorbidity, chronic medication,
25
26 HbA1c value, mortality and decision regarding limitation of life-sustaining care from
27
28 the patients' medical records (Take Care [CompuGroup Medical, Koblenz,
29
30 Germany]). International Classification of Disease (ICD) 10 codes were used to
31
32 identify comorbidity and previous history of diabetes. Additionally, data regarding
33
34 known diabetes diagnosis was extracted manually from the patients' medical records.
35
36
37
38
39 Data on body mass index (BMI), Simplified Acute Physiology Score (SAPS) 3, ICU
40
41 length of stay, duration of IMV and RRT were collected from the ICU electronic
42
43 patient data management system Clinisoft (GE, Barrington, IL).
44
45
46
47
48

49 *Prediabetes and Diabetes definitions*

50
51 Prediabetes and diabetes were diagnosed based on two complementary methods;
52
53 level of HbA1c at admission and previous medical history of diabetes, and
54
55 categorized into five groups:
56
57

58 (1) no diabetes (HbA1c <42 mmol/mol [6.0%] and no history of diabetes)
59
60

1
2
3 (2) prediabetes (HbA1c 42-47 mmol/mol [6.0-6.4%] and no history of diabetes)

4
5 (3) unknown diabetes (HbA1c \geq 48 mmol/mol [6.5 %] and no history of diabetes)

6
7 (4) controlled diabetes (HbA1c $<$ 52 mmol/mol [6.9 %] and previous history of
8
9 diabetes)

10
11 (5) uncontrolled diabetes (HbA1c \geq 52 mmol/mol [6.9 %] and previous history of
12
13 diabetes).

14
15 Cut off values for HbA1c according to the World Health Organization were used [12].

16
17 Individuals in group (2), (3), (4) and (5) were considered to have chronic dysglycemia
18
19 compared to those in group (1) labeled “no chronic dysglycemia”.

20 21 22 23 24 25 26 *Outcomes*

27
28 The primary outcome was the prevalence of chronic dysglycemia. Secondary
29
30 outcomes included 90-day mortality, ICU length of stay, duration of IMV, and RRT
31
32 use.

33 34 35 36 37 *Statistical Analysis*

38
39 We analyzed data using STATA version 12.1 (Stata Corp., College Station, Texas).
40
41 Categorical data is presented as numbers and percentages and compared using the
42
43 Fisher's exact test. Continuous data is summarized as median with interquartile
44
45 range (IQR) and compared using the Mann-Whitney U test. The prevalence of
46
47 chronic dysglycemia (primary outcome) was presented as percentages with 95%
48
49 confidence intervals (CI). We displayed time to death within 90 days using Kaplan-
50
51 Meier curves. Survival curves were compared using a log-rank test. We used
52
53 multivariable Cox regression analysis to assess the association between chronic
54
55 dysglycemia and 90-day mortality. We used multivariable linear regression analysis
56
57
58
59
60

1
2
3 to assess the association with ICU length of stay and duration of IMV. Both these
4
5 outcomes were found to be well approximated by log-normal distributions and were
6
7 therefore log-transformed before analysis with results presented as geometric means
8
9 (95% CI). We used multivariable logistic regression analysis to assess the
10
11 association with RRT use, before and after excluding patients with RRT as a
12
13 treatment limitation. All regression analyses were conducted using the following
14
15 models: adjusted for SAPS 3, age and sex, and adjusted for SAPS 3, age, sex,
16
17 hypertension, any malignancy, any treatment limitation on admission and chronic
18
19 corticosteroid use. A post-hoc exploratory comparison between subgroups was done
20
21 for 90 day mortality and RRT use. A two-sided P-value <0.05 was considered
22
23 statistically significant.
24
25
26
27
28
29

30 **Results**

31 *Patients*

32
33 A total of 584 patients with positive SARS-CoV-2 test were admitted to the study
34
35 ICUs during the study period. We excluded 225 patients without available HbA1c, six
36
37 pregnant patients, 16 readmissions and 29 patients without symptoms associated
38
39 with Covid-19. Therefore, we included 308 patients with available HbA1c for outcome
40
41 analysis. Among those 308 patients, 206 consequently admitted patients in which
42
43 HbA1c was included in the admission routine laboratory panel were used for
44
45 prevalence calculation (Figure 1). Baseline characteristics and treatment limitations
46
47 of the entire study population are detailed in Table 1.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics and treatment limitations

Characteristic	Chronic dysglycemia					P ^e
	No chronic dysglycemia	Prediabetes	Unknown diabetes	Controlled diabetes	Uncontrolled diabetes	
No. (%)	61 (19.8)	114 (37.0)	60 (19.4)	25 (8.11)	48 (15.5)	
Age, years	57 (51,63)	61 (53, 68)	60 (52, 68)	63 (57, 71)	62 (55,69)	0.03
Male sex	48 (78.6)	92 (80.7)	47 (78.3)	21 (84.0)	36 (75.0)	1.00
Body mass index ^a , kg/m ²	27 (25, 32)	27 (25, 30)	28 (25, 31)	29 (26, 32)	30 (26, 33)	0.97
HbA1c, mmol/mol	39 (36, 40)	44 (43, 46)	51 (49, 57)	47 (44, 49)	70 (61, 81)	<0.001
Diabetes treatment						
Diet only				6 (24.0)	2 (4.1)	
OAD only				17 (68)	19 (39.5)	
Insulin only				1 (4.0)	12 (25.0)	
OAD+Insulin				1 (4.0)	15 (31.2)	
Comorbidity						
Hypertension	18 (29.5)	40 (35.0)	23 (38.3)	16 (64.0)	34 (70.8)	0.02
Heart failure	6 (9.8)	5 (4.3)	6 (10.0)	0 (0.0)	3 (6.2)	0.24
Previous myocardial infarction	2 (3.2)	4 (3.5)	6 (10.0)	0 (0.0)	7 (14.5)	0.38
Chronic kidney disease	4 (6.5)	13 (11.4)	7 (11.6)	6 (24.0)	11 (22.9)	0.09
Liver disease	2 (3.2)	4 (3.5)	1 (1.6)	1 (4.0)	1 (2.0)	1.00
Any malignancy	0 (0.0)	8 (7.0)	2 (3.3)	2 (8.0)	4 (8.3)	0.04
Asthma/COPD	13 (21.3)	20 (17.5)	14 (23.3)	5 (20.0)	9 (18.7)	0.72
SAPS 3 ^b	53 (48, 60)	55 (49, 60)	57 (52, 62)	59 (52, 63)	56 (52, 69)	0.18
Chronic drug use						
Corticosteroids ^c	5 (8.20)	16 (14.04)	8 (13.3)	4 (16.0)	6 (12.5)	0.24
Immunosuppressive therapy ^d	1 (1.6)	8 (7.0)	3 (5.0)	1 (4.0)	1(2.0)	0.31
Treatment limitations ^f						
Any limitation	14 (22.9)	19 (16.6)	13 (21.6)	8 (32.0)	13 (27.0)	0.86
No RRT	5 (8.2)	7 (6.1)	5 (8.3)	5 (20.0)	6 (12.5)	1.00
No IMV	6 (9.8)	10 (8.7)	4 (6.6)	4 (16.0)	6 (12.5)	1.00
No CPR	9 (14.7)	19 (16.6)	12 (20.0)	8 (32.0)	12 (25.0)	0.36
No ECMO	7 (11.4)	3 (2.6)	5 (8.3)	3 (12.0)	3 (6.2)	0.15
Palliative care ^g	1 (1.6)	18 (16.5)	7 (12.2)	4 (16.6)	5 (10.8)	0.006

Data are n (%) or median (interquartile range)

HbA1c, glycated hemoglobin A1c; OAD, oral hypoglycemic agent; COPD, Chronic obstructive pulmonary disease; SAPS, Simplified Acute Physiology Score, 2 missing values (306 patients with data); RRT, renal replacement therapy; IMV, invasive mechanical ventilation; CPR, cardiopulmonary resuscitation

^aMissing data in 15 patients (293 patients with data)

^bMissing data in 2 patients (306 patients with data)

^cSystemic or inhaled corticosteroids

^dImmunosuppressive therapy was defined as: treatment with Metotrexate, Azathioprine, Cyclosporin, Tacrolimus, Infliximab

^eP values for the comparison between no chronic dysglycemia and chronic dysglycemia, Mann-Whitney U test was used for comparison of continuous data and Fischer's exact test for comparison of categorical data

^fDecision taken any time during ICU stay

^gDecision to go over to palliative care taken during ICU stay

Patients with chronic dysglycemia were older, were more likely to have hypertension, malignancy and/or chronic kidney disease, and had higher SAPS 3 than patients without chronic dysglycemia. Overall, 14 (22.9%) patients in the no chronic dysglycemia group and 53 (21.5%) patients in the chronic dysglycemia group

1
2
3 received one or more limitations of life-supporting therapies during their ICU stay.
4
5 “No Cardiopulmonary resuscitation (CPR)” was the most common treatment
6
7 limitation. We observed the highest proportion of limitations among patients with
8
9 known (controlled or uncontrolled) diabetes. Decision to switch to palliative care was
10
11 made in 1 (1.6%) patient in the no chronic dysglycemia group and 34 (13.8%)
12
13 patients in the chronic dysglycemia group (P=0.006). Cumulative percentage of
14
15 treatment limitations relative ICU admission is displayed in Figures S1-S4.
16
17
18
19
20

21 *Primary outcome*

22
23 In the nested cohort of 206 consecutive patients with available HbA1c, 169 (82.0%;
24
25 95% CI 76.1%-87.0%) were diagnosed with chronic dysglycemia. Prediabetes was
26
27 present in 83 (40.2%, 95% CI 33.5%-47.3%), unknown diabetes in 43 (20.9%, 95%
28
29 CI 15.5%-27.1%), well-controlled diabetes in 16 (7.8%, 95% CI 4.5%-12.3%), and
30
31 uncontrolled diabetes in 27 (13.1%, 95% CI 8.8%-18.5%) patients (Figure 2).
32
33
34
35
36
37

38 *Secondary outcomes*

39
40 Nine (14.7%) patients in the no chronic dysglycemia group and 62 (25.1%) patients
41
42 in the chronic dysglycemia group died within 90 days (P=0.09) (Table 2, Figure 3 and
43
44 Figure S5). ICU length of stay and duration of IMV were similar in the two groups.
45
46 IMV was delivered to 42 (68.8%) patients without chronic dysglycemia and to 187
47
48 (75.7%) patients with chronic dysglycemia (P=0.32). RRT was delivered to 17
49
50 (27.9%) no chronic dysglycemia patients and 42 (17.0%) chronic dysglycemia
51
52 patients (P=0.06) (Table 2 and Table 3).
53
54
55
56
57
58
59
60

Table 2. Secondary outcomes

Outcomes	Chronic dysglycemia					P ^a
	No chronic dysglycemia (n = 61)	Prediabetes (n = 114)	Unknown diabetes (n = 60)	Controlled diabetes (n = 25)	Uncontrolled diabetes (n = 48)	
90-day mortality, n (%)	9 (14.7)	28 (24.5)	12 (20.0)	7 (28.0)	15 (31.2)	0.09
ICU length of stay, days	9 (4, 25)	14 (6, 24)	13 (6, 28)	8 (5, 21)	11 (7, 22)	0.69
Invasive mechanical ventilation, days	16 (8, 29)	14 (10, 23)	15 (10, 27)	15 (6, 21)	14 (9, 22)	0.60
Renal replacement therapy, n (%)	17 (27.9)	22 (19.3)	11 (18.3)	1 (4.0)	8 (16.6)	0.06

Data are n (%) or median (interquartile range)

ICU lengths of stay (4 missing values because of transfer to other hospital)

^aP values for the comparison between no chronic dysglycemia and chronic dysglycemia, Mann-Whitney U test was used for comparison of continuous data and Fischer's exact test for comparison of categorical data.

Table 3. Multivariable regression analyses showing the association of chronic dysglycemia (versus no chronic dysglycemia) with secondary outcomes

Outcome measure	No Chronic Dysglycemia	Chronic Dysglycemia	Adjusted Risk Estimate (95% CI) ^a	P ^a	Adjusted Risk Estimate (95% CI) ^b	P ^b	Statistical test
90-day mortality n (%)	9/61 (14.7)	62/247 (25.1)	1.61 (0.79 to 3.26)	0.18	1.54 (0.74 to 3.19)	0.24	Cox regression
ICU length of stay, days							
All patients	9 (4, 25)	13 (6, 23)	1.06 (0.78 to 1.43)	0.70	1.05 (0.77 to 1.44)	0.71	Linear regression
ICU survivors ^c	9 (5, 27)	14 (7, 24)	1.04 (0.76 to 1.43)	0.75	1.05 (0.76 to 1.44)	0.75	Linear regression
Invasive mechanical ventilation duration, days							
All patients ^d	16 (8, 29)	14 (10, 23)	0.92 (0.68 to 1.23)	0.58	0.93 (0.69 to 1.24)	0.63	Linear regression
ICU survivors ^e	16 (8, 30)	15 (10, 23)	0.93 (0.70 to 1.23)	0.61	0.92 (0.70 to 1.22)	0.59	Linear regression
Renal replacement therapy, n (%)							
All patients	17/61 (27.9)	42/247 (17.0)	0.52 (0.26 to 1.02)	0.06	0.49 (0.24 to 0.99)	0.04	Logistic regression
Patients without treatment limitation as no RRT	17/57 (29.8)	42/224 (18.8)	0.52 (0.26 to 1.04)	0.10	0.52 (0.25 to 1.07)	0.08	Logistic regression

^aMultivariable models were adjusted for Simplified Acute Physiology Score (SAPS) 3, age and sex.

^bMultivariable models were adjusted for Simplified Acute Physiology Score (SAPS) 3, age, sex, hypertension, any malignancy, any treatment limitation on admission and chronic corticosteroid use

^cICU length of stay in ICU survivors, 260 observations

^dInvasive mechanical ventilation duration, 227 observations

^eInvasive mechanical ventilation duration in ICU survivors, 189 observations

1
2
3
4
5 On multivariable regression analysis we observed a numerically higher mortality
6 (adjusted HR 1.54, 95% CI 0.74-3.19, P=0.24) and significantly lower RRT use
7 (adjusted OR 0.49, 95% CI 0.24-0.99, P=0.04) in patients with chronic dysglycemia
8 (Table 3). No association with RRT was observed after exclusion of patients with “No
9 RRT” as treatment limitation. In the post-hoc exploratory comparison between
10 subgroups, RRT use was higher in the no diabetes group compared to the controlled
11 diabetes group, as well as in the uncontrolled diabetes compared to controlled
12 diabetes group (Table S1). Individuals with uncontrolled diabetes had the lowest
13 probability of survival followed by individuals with controlled diabetes and
14 prediabetes. The highest probability of survival was observed among patients with no
15 chronic dysglycemia and prediabetes, respectively (Figure S5). However, we
16 observed no statistically significant differences in mortality in the post-hoc
17 comparison of subgroups (Table S1).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Discussions**

41 *Key findings*

42 We performed a multicenter observational investigation to determine the prevalence
43 of chronic dysglycemia and its impact on clinical outcomes among Covid-19 patients
44 admitted to ICU. Using available information about the patients’ diabetic status in
45 combination with routine HbA1c assessment, we found that 82% had chronic
46 dysglycemia with two thirds having either prediabetes or undiagnosed diabetes. We
47 observed numerically higher 90-day mortality in patients with chronic dysglycemia,
48 with the highest mortality (31%) observed among those with uncontrolled diabetes.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Conversely, the proportion of patients receiving RRT was lower among patients with
4 chronic dysglycemia even when patients without “No RRT” as treatment limitation
5 were considered separately. We found no association of chronic dysglycemia with
6 ICU length of stay or duration of IMV.
7
8
9
10
11
12
13

14 *Relationship with previous studies*

15
16 A global meta-analysis of more than 16000 ICU patients with Covid-19 suggests a
17 pooled prevalence of known diabetes between 23-31% [13], close to the observed
18 prevalence in our study (21%). However, few studies have used additional HbA1c
19 measurements to assess the actual prevalence of chronic dysglycemia, including
20 prediabetes and undiagnosed diabetes. One such ICU study from Austria found a
21 prevalence of chronic dysglycemia of 85%, which is in close agreement with our
22 findings [14]. However, the Austrian study did not assess consecutive patients and
23 may therefore be prone to selection bias.
24
25
26
27
28
29
30
31
32
33
34

35 Our findings indicate that chronic dysglycemia is more common in Covid-19 patients
36 than in ICU patients with other admission diagnoses. In fact, in a pre-Covid-19 cohort
37 of general ICU patients we found a corresponding dysglycemia prevalence of 33%
38 [10]. The relationship between severe SARS-CoV-2 infection and dysglycemia has
39 different potential explanations. SARS-CoV-2 enters cells in various organs, including
40 the pancreas, via angiotensin-converting enzyme II (ACE2). As ACE2 is involved in
41 regulating pancreatic beta-cell function, a link between SARS-CoV-2 infection and
42 beta-cell dysfunction and diabetes development has been suggested [15].
43
44
45
46
47
48
49
50
51
52

53 Interestingly, the prevalence of elevated HbA1c below the diabetes diagnostic
54 threshold (prediabetes) was markedly higher in our Covid-19 cohort than in our
55 previous pre-Covid-19 cohort (40% vs 9%). It is possible that the duration of Covid-
56
57
58
59
60

1
2
3 19 symptoms before ICU admission (typically ten days in the literature [16]) was
4
5 sufficient to trigger new onset hyperglycemia with mildly elevated HbA1c.
6

7
8 In addition to the above speculations about SARS-CoV-2 as a *cause* of dysglycemia,
9
10 there is also evidence suggesting that patients with preexisting dysglycemia are
11
12 prone to a more severe course of Covid-19. For example, some studies have shown
13
14 that hospitalized SARS-CoV-2 positive with prediabetes, unknown diabetes, and
15
16 known poorly controlled diabetes are at increased risk of SARS-CoV-2 associated
17
18 respiratory failure requiring intensive care [17]. A higher burden of comorbidities,
19
20 hyperglycemia *per se*, and chronic low-grade inflammation in diabetes may explain
21
22 this observation [18].
23
24

25
26 Wang et al identifies fasting glucose as an independent predictor for 28-day mortality
27
28 in hospitalized individuals with Covid-19 and previously unknown diabetes. However,
29
30 HbA1c was not assessed and interference from stress hyperglycemia might have led
31
32 to the different results compared to our study [19].
33
34

35
36 Others [20], identified an increased risk of death in individuals with diabetes and
37
38 increasing levels of HbA1c above 48 mmol/mol and known diabetes in a large cohort
39
40 of hospitalized patients, but not in critically ill individuals.
41

42
43 Whether chronic dysglycemia is associated with worse outcomes among Covid-19
44
45 patients admitted to ICU remains uncertain. Dennis et al [21] found increased
46
47 mortality risk at 30 days (HR 1.23 [95% CI 1.14, 1.32]) compared to patients with no
48
49 diabetes in patients admitted to the high Dependency Unit or ICU, but did not take
50
51 HbA1c into consideration. A multicenter study from France including 410 ICU
52
53 patients with Covid-19, found no association between the severity of dysglycemia
54
55 and tracheal intubation and/or death within 7 days of admission in patients with
56
57 diabetes than in those without diabetes [22]. This is in accordance with the findings of
58
59
60

1
2
3 our study. In contrast, others found higher mortality in the subgroup of mechanically
4 ventilated patients with diabetes [14].
5
6

7 We previously demonstrated an independent association between chronic
8 dysglycemia and need for RRT in critically ill non-Covid-19 patients [10]. This
9 association was, however, not found in the present study. In fact, we observed a
10 higher proportion of patients requiring RRT among our patients without chronic
11 dysglycemia and an inverse association between chronic dysglycemia and RRT use.
12
13 Only one individual in the controlled diabetes subgroup received RRT during ICU
14 stay. We believe this surprising finding may be due to treatment limitations. In fact,
15 after exclusion of patients with treatment limitation “not for RRT”, we observed no
16 statistically significant association between chronic dysglycemia and RRT use.
17
18 Limitations in life-sustaining care were more common in the known diabetes groups
19 (well controlled and uncontrolled diabetes) than in all other groups. We cannot
20 exclude the possibility that patients with severe acute or chronic kidney injury did not
21 reach the ICU because of treatment limitation decisions made at hospital arrival or on
22 the medical ward. This might have influenced the number of patients with kidney
23 injury reaching the ICU, affecting predominantly patients with chronic dysglycemia,
24 as they are usually older and have multiple comorbidities.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 *Strengths and limitations*

48
49 Our study has several strengths. It is the first to assess the prevalence of chronic
50 dysglycemia in an ICU population with Covid-19 based on additional quantification of
51 admission HbA1c. This approach reduced bias due to events that would have
52 influenced HbA1c values obtained before ICU admission. We restricted the
53 prevalence assessment to a cohort of patients who were admitted to ICUs where
54
55
56
57
58
59
60

1
2
3 HbA1c was part of the routine laboratory panel, thereby reducing the risk of
4
5 ascertainment bias. Additionally, by measuring HbA1c in all patients admitted to the
6
7 ICU we identified 169 (82%) individuals with chronic dysglycemia and 86 (41.7%)
8
9 with diabetes. If HbA1c would not have been measured routinely at ICU admission,
10
11 we would only have identified 43 (20.9%) individuals with diabetes. Furthermore, we
12
13 considered treatment limitations in our analysis of clinical outcomes, thereby
14
15 reducing the risk of treatment selection bias. Finally, we included patients admitted to
16
17 ten ICUs in three University hospitals, thus providing a degree of external validity for
18
19 applying our findings to similar settings.
20
21
22

23
24 Our study has limitations. We lack data on conditions and treatment that might have
25
26 influenced admission HbA1c, such as haemoglobinopathies and blood transfusion
27
28 before ICU admission. Since interviews with patients or relatives were not performed,
29
30 a degree of misclassification due to non-documented dysglycemia diagnoses cannot
31
32 be ruled out. However, such interviews would have been logistically difficult during
33
34 the ongoing pandemic. We used an HbA1c cutoff of 42-47 mmol/mol (6.0-6.4%) to
35
36 classify prediabetes. If we instead had used the cutoff suggested by the American
37
38 Diabetes Association (39-47 mmol/mol [5.7-6.4%]), our prevalence of chronic
39
40 dysglycemia would have increased from 82.0% to 91.3%. This approach did not,
41
42 however, alter the association with the secondary outcomes (data not shown). In
43
44 addition, we lack information about glycemic control during intensive care, which
45
46 might have modified clinical outcomes.
47
48
49

50
51 The observational nature of the study does not imply causation. Generalizability of
52
53 our results is limited to populations with similar health care systems and similar legal
54
55 frame-works for decisions on treatment limitations. Finally, the limited sample size
56
57
58
59
60

1
2
3 may limit the conclusion regarding secondary outcomes that can be drawn from the
4
5 data.
6
7
8
9

10 **Conclusion**

11
12 In our multicenter cohort of Covid-19 patients admitted to the ICU, HbA1c screening
13
14 diagnosed chronic dysglycemia in four out of five patients with the majority having
15
16 either prediabetes or previously undiagnosed diabetes. Chronic dysglycemia was not
17
18 significantly associated with mortality, ICU length of stay, duration of invasive
19
20 mechanical ventilation or renal replacement therapy use after considering treatment
21
22 limitations. These findings indicate that chronic dysglycemia may be a risk factor for
23
24 severe Covid-19. However, Covid-19 prognosis in the ICU does not appear to be
25
26 modified by chronic dysglycemia.
27
28
29
30
31
32
33
34

35 **Author Contributions:**

36
37 AB, SR, MC, JG, AO, CS and JM contributed to the concept and design of the study.
38
39

40
41 AB, SR, CH and JM collected data.
42

43
44 AB, SR, CH, JG, MC, CS, AO and JM contributed to the analysis and interpretation of
45
46 data.
47

48
49 AB and JM drafted the manuscript.
50

51
52 All authors critically reviewed and approved the final manuscript.
53

54
55 AB accepts full responsibility for the work and the conduct of the study, had access to
56
57 the data, and controlled the decision to publish.
58
59
60

Funding AB and JM were supported by Region Stockholm (clinical research appointment and ALF project grants), grant number 580282.

A non-peer-reviewed version of this article has been a part of a publicly defended PhD thesis ISBN 978-91-8016-719-2 and was submitted to Karolinska Institute Open Archive, available at <https://openarchive.ki.se/xmlui/handle/10616/48203> on 19 September 2022.

Competing interest: The authors have no competing interest relevant to this work.

Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval Statement: The study was approved by the Swedish Ethical Review Authority (approval number 2020-01302).

References

- [1] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases* 2020;94:91-5. doi:10.1016/j.ijid.2020.03.017
- [2] Liu Y, Lu R, Wang J, Cheng Q, Zhang R, Zhang S, et al. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. *BMC Endocrine Disorders* 2021;21(1):1-10. doi:10.1186/s12902-021-00717-6
- [3] Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal* 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
- [4] Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol* 2020;127:104354. doi:10.1016/j.jcv.2020.104354
- [5] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020;395. doi:10.1016/S0140-6736(20)30566-3
- [6] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/metabolism research and reviews* 2020:e3319.

- 1
2
3 [7] Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J, et al. Clinical Features and Risk
4 Factors of ICU Admission for COVID-19 Patients with Diabetes. *Journal of Diabetes*
5 *Research* 2020;2020:5237840. doi:10.1155/2020/5237840
6
7 [8] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk
8 Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care
9 Units in Lombardy, Italy. *JAMA internal medicine* 2020;180(10):1345-55.
10 doi:10.1001/jamainternmed.2020.3539
11 [9] Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed
12 diabetes in adults. *Diabetes Research and Clinical Practice* 2014;103(2):150-60.
13 doi:https://doi.org/10.1016/j.diabres.2013.11.001
14 [10] Balintescu A, Palmgren I, Lipcsey M, Oldner A, Larsson A, Cronhjort M, et al.
15 Prevalence and impact of chronic dysglycemia in intensive care unit patients-A
16 retrospective cohort study. *Acta Anaesthesiol Scand* 2021;65(1):82-91.
17 doi:10.1111/aas.13695
18 [11] Erik von Elm DGA, Matthias Egger, Stuart J. Pocock, Peter C. Gøtzsche, and Jan P.
19 Vandembroucke. The Strengthening the Reporting of Observational Studies in
20 Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies.
21 *Annals of Internal Medicine* 2007;147(8):573-7. doi:10.7326/0003-4819-147-8-
22 200710160-00010 %m 17938396
23 [12] Organisation WH. World Health Organisation. Use of Glycated Haemoglobin
24 (HbA1c) in the Diagnosis of Diabetes Mellitus,
25 [https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-\(-hba1c\)-in-](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(-hba1c)-in-diagnosis-of-diabetes-mellitus)
26 [diagnosis-of-diabetes-mellitus](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(-hba1c)-in-diagnosis-of-diabetes-mellitus); [accessed 07 Fenruary 2022].
27
28 [13] Tan E, Song J, Deane AM, Plummer MP. Global Impact of Coronavirus Disease 2019
29 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis.
30 *Chest* 2021;159(2):524-36. doi:https://doi.org/10.1016/j.chest.2020.10.014
31
32 [14] Klein SJ, Mayerhöfer T, Fries D, Preuß Hernández C, Joannidis M, Collaborators, et
33 al. Elevated HbA1c remains a predominant finding in severe COVID-19 and may be
34 associated with increased mortality in patients requiring mechanical ventilation.
35 *Critical Care* 2021;25(1):1-4. doi:10.1186/s13054-021-03730-2
36
37 [15] Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for
38 relationship between SARS-CoV-2 and diabetes. *Acta Physiologica* 2021;233(4):1-13.
39 doi:10.1111/apha.13733
40
41 [16] Larsson E, Brattstrom O, Agvald-Ohman C, Grip J, Jalde FC, Stralin K, et al.
42 Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary
43 hospital in Stockholm, Sweden. *Acta anaesthesiologica Scandinavica* 2021;65(1):76-
44 81. doi:10.1111/aas.13694
45
46 [17] Rysz S, Jonsson Fagerlund M, Rimes-Stigare C, Larsson E, Campoccia Jalde F,
47 Mårtensson J. Chronic dysglycemia and risk of SARS-CoV-2 associated respiratory
48 failure in hospitalized patients. *Acta anaesthesiologica Scandinavica* 2022;66(1):48-
49 55. doi:10.1136/bjsports-2021-104080.
50
51 [18] Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the
52 Interrelationship and Risks for a Severe Course. *Frontiers in endocrinology*
53 2021;12:649525. doi:10.3389/fendo.2021.649525
54
55 [19] Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at
56 admission is an independent predictor for 28-day mortality in patients with COVID-19
57 without previous diagnosis of diabetes: a multi-centre retrospective study.
58 *Diabetologia* 2020;63(10):2102-11. doi:10.1007/s00125-020-05209-1
59
60 [20] Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for
COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a


- 1
2
3 population-based cohort study. *The lancet Diabetes & endocrinology* 2020;8(10):823-
4 33. doi:10.1016/S2213-8587(20)30271-0
5 [21] Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al.
6 Type 2 Diabetes and COVID-19-Related Mortality in the Critical Care Setting: A
7 National Cohort Study in England, March-July 2020. *Diabetes Care* 2021;44(1):50-7.
8 doi:10.2337/dc20-1444
9 [22] Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic
10 characteristics and prognosis of inpatients with COVID-19 and diabetes: the
11 CORONADO study. *Diabetologia* 2020;63(8):1500-15. doi:10.1007/s00125-020-
12 05180-x
13
14
15

16 Figure legends

17 **Figure 1.** Flow chart of study population

18 **Figure 2.** Prevalence of prediabetes, unknown diabetes and known diabetes among 206
19 consecutive ICU patients with Covid-19

20 **Figure 3.** Probability of survival in no chronic dysglycemia patients and in patients with
21 chronic dysglycemia
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Prevalence of prediabetes, unknown diabetes and known diabetes among 206 consecutive ICU patients with Covid-19

144x102mm (144 x 144 DPI)




Figure 3. Probability of survival in no chronic dysglycemia patients and in patients with chronic dysglycemi

770x521mm (144 x 144 DPI)

Table S1: Post-hoc exploratory comparison between the subgroups for 90 days mortality and Renal replacement therapy

Subgroups	90 day mortality		Renal replacement therapy	
	N (%)	p	N (%)	p
No chronic dysglycemia vs Prediabetes	9/61 (14.7) vs 28/114 (24.5)	0.17	17/61 (27.8) vs 22/114 (19.2)	0.25
No chronic dysglycemia vs Unknown diabetes	9/61 (14.7) vs 12/60 (20.0)	0.48	17/61 (27.8) vs 11/60 (18.3)	0.28
No chronic dysglycemia vs Controlled diabetes	9/61 (14.7) vs 7/25 (28.0)	0.22	17/61 (27.8) vs 1/25 (4.0)	0.01
No chronic dysglycemia vs Uncontrolled diabetes	9/61 (14.7) vs 15/48 (31.2)	0.06	17/61 (27.8) vs 8/48 (16.6)	0.25
Prediabetes vs Unknown diabetes	28/114 (24.5) vs 12/60 (20.0)	0.57	22/114 (19.2) vs 11/60 (18.3)	1
Prediabetes vs Controlled diabetes	28/114 (24.5) vs 7/25 (28.0)	0.79	22/114 (19.2) vs 1/25 (4.0)	0.07
Prediabetes vs Uncontrolled diabetes	28/114 (24.5) vs 15/48 (31.2)	0.43	22/114 (19.2) vs 8/48 (16.6)	0.8
Unknown diabetes vs Controlled diabetes	12/60 (20.0) vs 7/25 (28.0)	0.41	11/60 (18.3) vs 1/25 (4.0)	0.1
Unknown diabetes vs Uncontrolled diabetes	12/60 (20.0) vs 15/48 (31.2)	0.18	11/60 (18.3) vs 8/48 (16.6)	1
Controlled vs Uncontrolled diabetes	7/25 (28.0) vs 15/48 (31.2)	0.77	1/25 (4.0) vs 8/48 (16.6)	0.01
No chronic dysglycemia and prediabetes vs unknown and known diabetes	37/175 (21.1) vs 34/133 (25.5)	0.41	39/175 (22.2) vs 20/133 (15.0)	0.14

P values calculated with Fischer's exact test




Figure S1. Cumulative percentage of patients with a treatment limitation: no renal replacement therapy. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S2. Cumulative percentage of patients with a treatment limitation: no cardiopulmonary resuscitation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S3. Cumulative percentage of patients with a treatment limitation: no invasive mechanical ventilation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S4. Cumulative percentage of patients with a treatment limitation: no extracorporeal membrane oxygenation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S5. Probability of survival in the study groups

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Page references for document: **Chronic dysglycemia in critically ill patients with Covid-19 – a retrospective cohort study**

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods⁴			
Study design	4	Present key elements of study design early in the paper	4, 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5-7 NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5-6, Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 8 NA NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8-9, Figure 1 Figure 1 Figure 1

1	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
2				Table
3				1
4			(b) Indicate number of participants with missing data for each variable of interest	Table
5				1
6			(c) Summarise follow-up time (eg, average and total amount)	NA
7				
8	Outcome data	15*	Report numbers of outcome events or summary measures over time	10-11
9				Table
10				2-3

For peer review only

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 2 3 4 5 6 7 8	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10-11 Table 3
9 10 11 12	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11 Figure 2,3,S1- 4, S5
13	Discussion			
14	Key results	18	Summarise key results with reference to study objectives	11
15 16 17	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
18 19 20 21	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
22	Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
23	Other information			
24 25 26	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Prevalence and impact of chronic dysglycemia among patients with Covid-19 in Swedish intensive care units: a multicenter, retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-071330.R2
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2023
Complete List of Authors:	Balintescu, Anca; Karolinska Institute, Department of Clinical Science and Education, Södersjukhuset Rysz, Susanne; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Hertz, Carl; Stockholm South General Hospital Anaesthesia Department ICU Grip, Jonathan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Cronhjort, Maria; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Oldner, Anders; Karolinska Institute, Department of Perioperative Medicine and Intensive Care Svensen, Christer; Karolinska Institute, Department of Clinical Science and Education Södersjukhuset Mårtensson, Johan; Karolinska Institute, Department of Perioperative Medicine and Intensive Care
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Adult intensive & critical care < INTENSIVE & CRITICAL CARE, COVID-19, DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and impact of chronic dysglycemia among patients with Covid-19 in Swedish intensive care units: a multicenter, retrospective cohort study

Anca Balintescu, MD, PhD^{1, 2}; Susanne Rysz, MD^{3, 4}; Carl Hertz, MD²; Jonathan Grip, MD, PhD^{3, 5}; Maria Cronhjort, MD, PhD^{1, 2}; Anders Oldner MD, PhD^{3, 6}; Christer Svensen MD, PhD^{1, 2}; Johan Mårtensson, MD, PhD^{3, 6}

¹ Department of Clinical Science and Education Karolinska Institute, Unit of Anesthesiology and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

² Department of Anesthesia and Intensive Care, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden

³ Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Norrbacka S2:05, SE-17176 Stockholm, Sweden

⁴ Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden

⁵ Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden

⁶ Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Norrbacka S2:05, SE-17176 Stockholm, Sweden

Corresponding Author:

Anca Balintescu, ANOPIVA, South General Hospital, Sjukhusbacken 10, 11883 Stockholm, Sweden. Phone: +46 (0)722 7023 83. Fax: +46 (0)8-616 22 08. Email: anca.balintescu@ki.se

Keywords: HbA1c, ICU, Covid-19, prevalence, glycemic control, diabetes

Abstract

Objective: Using glycated hemoglobin A1c (HbA1c) screening, we aimed to determine the prevalence of chronic dysglycemia among patients with Covid-19 admitted to the intensive care unit (ICU). Additionally, we aimed to explore the association between chronic dysglycemia and clinical outcomes related to ICU stay.

Design: Multicenter retrospective observational study

Setting: ICUs in three hospitals in Stockholm, Sweden

Participants: Covid-19 patients admitted to the ICU between 5 March and 13 August 2020 with available HbA1c at admission. Chronic dysglycemia was determined based on previous diabetes history and HbA1c.

Primary and secondary outcomes: Primary outcome was the actual prevalence of chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among Covid-19 patients. Secondary outcome was the association of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive mechanical ventilation (IMV), and renal replacement therapy (RRT), accounting for treatment selection bias.

Results: A total of 308 patients with available admission HbA1c were included. Chronic dysglycemia prevalence assessment was restricted to 206 patients admitted ICUs in which HbA1c was measured on all admitted patients. Chronic dysglycemia was present in 82.0% (95% CI 76.1%-87.0%) of patients, with prediabetes present in 40.2% (95% CI 33.5%-47.3%), unknown diabetes in 20.9% (95% CI 15.5%-27.1%), well-controlled diabetes in 7.8% (95% CI 4.5%-12.3%), and uncontrolled diabetes in 13.1% (95% CI 8.8%-18.5%). All patients with available HbA1c were included for the analysis of the relationship between chronic dysglycemia and secondary outcomes.

1
2
3 We found no independent association between chronic dysglycemia and 90-day
4 mortality, ICU length of stay, or duration of IMV. After excluding patients with specific
5 treatment limitations, no association between chronic dysglycemia and RRT use was
6 observed.
7
8
9
10
11

12 **Conclusions:** In our cohort of critically ill Covid-19 patients, the prevalence of chronic
13 dysglycemia was 82%. We found no robust associations between chronic dysglycemia
14 and clinical outcomes when accounting for treatment limitations.
15
16
17
18
19
20
21
22
23

24 **Strengths and limitations of this study**

- 25 • Presents prevalence of chronic dysglycemia in an ICU population with Covid-
26 19 based on additional quantification of admission HbA1c
- 27 • Actual prevalence of chronic dysglycemia calculation in all ICU admitted
28 patients, reducing the risk of ascertainment bias
- 29 • Treatment limitations were considered in the analysis of clinical outcomes,
30 thereby reducing the risk of treatment selection bias.
- 31 • We lack data on glycemetic control during ICU stay, that might have influenced
32 clinical outcomes
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Background**

51 Diabetes has been identified as a frequent comorbidity in patients with Covid-19, with
52 a prevalence ranging from 7.4% to 34.3% among those requiring hospitalization [1-
53 3]. A meta-analysis published in April 2020 found diabetes to be the second most
54 frequent comorbidity in patients with Covid-19 admitted to the intensive care unit
55
56
57
58
59
60

1
2
3 (ICU) [4]. Furthermore, Covid-19 patients with diabetes appear to have a significantly
4
5 higher risk of ICU admission and worse prognosis than Covid-19 patients without
6
7 diabetes [4-6]. Particularly, a glycated hemoglobin A1c (HbA1c) level above 7% (53
8
9 mmol/mol) was identified as risk factor for ICU admission [7].

10
11
12 Recent data also indicates that diabetes is associated with worse prognosis among
13
14 ICU patients with Covid-19 [8]. However, these studies did not include HbA1c
15
16 measurements to identify patients with prediabetes or previously undiagnosed
17
18 diabetes. This is an important limitation since both prediabetes and diabetes is
19
20 considerably under-diagnosed both in the community [9] and in the ICU [10].

21
22 Additionally, a history of diabetes diagnosis and HbA1c at ICU admission, measured
23
24 in consecutively admitted patients, is important in determining the true prevalence of
25
26 chronic dysglycemia in the critically ill Covid-19 population. Finally, information about
27
28 limitations of life-sustaining treatment were not considered in previous outcome
29
30 analyses. This is unfortunate since the presence of such limitations may introduce
31
32 treatment selection bias.

33
34 We therefore conducted a multicenter observational study using quantification of
35
36 HbA1c and information about diabetes history to determine the actual prevalence of
37
38 chronic dysglycemia (prediabetes, unknown diabetes, or known diabetes) among
39
40 Covid-19 patients admitted to ICU. In addition, we aimed to explore the relationship
41
42 of chronic dysglycemia with 90-day mortality, ICU length of stay, duration of invasive
43
44 mechanical ventilation (IMV) and severe acute kidney injury requiring renal
45
46 replacement therapy (RRT) accounting for treatment selection bias. We hypothesised
47
48 that prevalence of chronic dysglycemia in Covid-19 patients admitted to the ICU
49
50 exceeds the prevalence of chronic dysglycemia in the non Covid-19 critically ill
51
52
53
54
55
56
57
58
59
60

1
2
3 population. Moreover, we hypothesised that such chronic dysglycemia would be
4
5 associated with worse clinical outcomes during ICU stay in patients with Covid-19.
6
7
8
9

10 11 12 **Material and Methods**

13
14 The study was approved by the Swedish Ethical Review Authority (approval number
15
16 2020-01302, amendment 2020-02890) with a waiver of informed consent. The study
17
18 was performed in accordance with the Helsinki Declaration and reported in
19
20 conformity with the STROBE statement [11]
21
22

23
24 Patient and Public Involvement statement: The study is based on data that was
25
26 collected during the ongoing Covid-19 pandemic in a quality register. No intervention
27
28 was applied to the individual patient. The public and patients were not involved in the
29
30 design of the study. Results are to be disseminated to the public and scientific
31
32 community through publication in peer-reviewed journal with open access.
33
34
35
36

37 *Study design*

38
39 We conducted a multicenter, retrospective observational study of adult (≥ 18 years)
40
41 patients with a positive polymerase chain reaction (PCR) for severe acute respiratory
42
43 syndrome coronavirus 2 (SARS-CoV-2) admitted to ten ICUs in three hospitals in
44
45 Stockholm, Sweden between March 5th and August 13th, 2020 (first wave). We
46
47 excluded patients without HbA1c obtained on admission to the ICU, patients in the
48
49 third trimester of pregnancy and patients with a primary admission diagnosis other
50
51 than Covid-19. In patients with multiple ICU admissions, only the first admission was
52
53 considered. All included patients were assessed in the outcome analyses.
54
55
56
57

58 Assessment of chronic dysglycemia prevalence was restricted to a nested cohort of
59
60

1
2
3 patients from ICUs in which HbA1c measurement was included in the routine
4
5 laboratory panel performed on all consecutive admissions. In the prevalence
6
7 analysis, we therefore excluded patients with available HbA1c who were admitted to
8
9 ICUs in which HbA1c was measured only at the discretion of the treating clinicians.
10
11
12
13

14 *Data collection*

15
16 HbA1c was measured in whole blood at ICU admission using the VARIANT II
17
18 TURBO Hemoglobin Testing System analyzer (Bio-Rad Laboratories GmbH) and
19
20 was reported in mmol/mol (IFCC calibrated) and in %. HbA1c was measured as part
21
22 of routine care in three ICUs and at the discretion of the treating clinician in seven
23
24 ICUs. We collected information on demographics, comorbidity, chronic medication,
25
26 HbA1c value, mortality and decision regarding limitation of life-sustaining care from
27
28 the patients' medical records (Take Care [CompuGroup Medical, Koblenz,
29
30 Germany]). International Classification of Disease (ICD) 10 codes were used to
31
32 identify comorbidity and previous history of diabetes. Additionally, data regarding
33
34 known diabetes diagnosis was extracted manually from the patients' medical records.
35
36
37
38
39 Data on body mass index (BMI), Simplified Acute Physiology Score (SAPS) 3, ICU
40
41 length of stay, duration of IMV and RRT were collected from the ICU electronic
42
43 patient data management system Clinisoft (GE, Barrington, IL).
44
45
46
47
48

49 *Prediabetes and Diabetes definitions*

50
51 Prediabetes and diabetes were diagnosed based on two complementary methods;
52
53 level of HbA1c at admission and previous medical history of diabetes, and
54
55 categorized into five groups:
56
57

58 (1) no diabetes (HbA1c <42 mmol/mol [6.0%] and no history of diabetes)
59
60

1
2
3 (2) prediabetes (HbA1c 42-47 mmol/mol [6.0-6.4%] and no history of diabetes)

4
5 (3) unknown diabetes (HbA1c \geq 48 mmol/mol [6.5 %] and no history of diabetes)

6
7 (4) controlled diabetes (HbA1c $<$ 52 mmol/mol [6.9 %] and previous history of
8
9 diabetes)

10
11 (5) uncontrolled diabetes (HbA1c \geq 52 mmol/mol [6.9 %] and previous history of
12
13 diabetes).

14
15
16 In Sweden, the diagnosis of prediabetes and diabetes is based on the World Health
17
18 Organisation's (WHO) HbA1c cut off values [12], not the American Diabetes
19
20 Association's (ADA). Therefore, we used the WHO criteria to classify the study
21
22 groups in our research.

23
24
25 Individuals in group (2), (3), (4) and (5) were considered to have chronic dysglycemia
26
27 compared to those in group (1) labeled "no chronic dysglycemia".
28
29

30 31 32 33 *Outcomes*

34
35 The primary outcome was the prevalence of chronic dysglycemia. Secondary
36
37 outcomes included 90-day mortality, ICU length of stay, duration of IMV, and RRT
38
39 use.
40
41

42 43 44 45 *Statistical Analysis*

46
47 We analyzed data using STATA version 12.1 (Stata Corp., College Station, Texas).
48
49 Categorical data is presented as numbers and percentages and compared using the
50
51 Fisher's exact test. Continuous data is summarized as median with interquartile
52
53 range (IQR) and compared using the Mann-Whitney U test. The prevalence of
54
55 chronic dysglycemia (primary outcome) was presented as percentages with 95%
56
57 confidence intervals (CI). We displayed time to death within 90 days using Kaplan-
58
59
60

1
2
3 Meier curves. Survival curves were compared using a log-rank test. We used
4
5 multivariable Cox regression analysis to assess the association between chronic
6
7 dysglycemia and 90-day mortality. We used multivariable linear regression analysis
8
9 to assess the association with ICU length of stay and duration of IMV. Both these
10
11 outcomes were found to be well approximated by log-normal distributions and were
12
13 therefore log-transformed before analysis with results presented as geometric means
14
15 (95% CI). We used multivariable logistic regression analysis to assess the
16
17 association with RRT use, before and after excluding patients with RRT as a
18
19 treatment limitation. All regression analyses were conducted using the following
20
21 models: adjusted for SAPS 3, age and sex, and adjusted for SAPS 3, age, sex,
22
23 hypertension, any malignancy, any treatment limitation on admission and chronic
24
25 corticosteroid use. A post-hoc exploratory comparison between subgroups was done
26
27 for 90 day mortality and RRT use. A two-sided P-value <0.05 was considered
28
29 statistically significant.
30
31
32
33
34
35
36
37

38 **Results**

39 *Patients*

40
41 A total of 584 patients with positive SARS-CoV-2 test were admitted to the study
42
43 ICUs during the study period. We excluded 225 patients without available HbA1c, six
44
45 pregnant patients, 16 readmissions and 29 patients without symptoms associated
46
47 with Covid-19. Therefore, we included 308 patients with available HbA1c for outcome
48
49 analysis. Among those 308 patients, 206 consequently admitted patients in which
50
51 HbA1c was included in the admission routine laboratory panel were used for
52
53 prevalence calculation (Figure 1). Baseline characteristics and treatment limitations
54
55 of the entire study population are detailed in Table 1.
56
57
58
59
60

Table 1. Baseline characteristics and treatment limitations

Characteristic	Chronic dysglycemia					P ^e
	No chronic dysglycemia	Prediabetes	Unknown diabetes	Controlled diabetes	Uncontrolled diabetes	
No. (%)	61 (19.8)	114 (37.0)	60 (19.4)	25 (8.1)	48 (15.5)	
Age, years	57 (51.63)	61 (53, 68)	60 (52, 68)	63 (57, 71)	62 (55.69)	0.03
Male sex	48 (78.6)	92 (80.7)	47 (78.3)	21 (84.0)	36 (75.0)	1.00
Body mass index ^a , kg/m ²	27 (25, 32)	27 (25, 30)	28 (25, 31)	29 (26, 32)	30 (26, 33)	0.97
HbA1c, mmol/mol	39 (36, 40)	44 (43, 46)	51 (49, 57)	47 (44, 49)	70 (61, 81)	<0.001
Diabetes treatment						
Diet only				6 (24.0)	2 (4.1)	
OAD only				17 (68)	19 (39.5)	
Insulin only				1 (4.0)	12 (25.0)	
OAD+Insulin				1 (4.0)	15 (31.2)	
Comorbidity						
Hypertension	18 (29.5)	40 (35.0)	23 (38.3)	16 (64.0)	34 (70.8)	0.02
Heart failure	6 (9.8)	5 (4.3)	6 (10.0)	0 (0.0)	3 (6.2)	0.24
Previous myocardial infarction	2 (3.2)	4 (3.5)	6 (10.0)	0 (0.0)	7 (14.5)	0.38
Chronic kidney disease	4 (6.5)	13 (11.4)	7 (11.6)	6 (24.0)	11 (22.9)	0.09
Liver disease	2 (3.2)	4 (3.5)	1 (1.6)	1 (4.0)	1 (2.0)	1.00
Any malignancy	0 (0.0)	8 (7.0)	2 (3.3)	2 (8.0)	4 (8.3)	0.04
Asthma/COPD	13 (21.3)	20 (17.5)	14 (23.3)	5 (20.0)	9 (18.7)	0.72
SAPS 3 ^b	53 (48, 60)	55 (49, 60)	57 (52, 62)	59 (52, 63)	56 (52, 69)	0.18
Chronic drug use						
Corticosteroids ^c	5 (8.20)	16 (14.04)	8 (13.3)	4 (16.0)	6 (12.5)	0.24
Immunosuppressive therapy ^d	1 (1.6)	8 (7.0)	3 (5.0)	1 (4.0)	1(2.0)	0.31
Treatment limitations ^f						
Any limitation	14 (22.9)	19 (16.6)	13 (21.6)	8 (32.0)	13 (27.0)	0.86
No RRT	5 (8.2)	7 (6.1)	5 (8.3)	5 (20.0)	6 (12.5)	1.00
No IMV	6 (9.8)	10 (8.7)	4 (6.6)	4 (16.0)	6 (12.5)	1.00
No CPR	9 (14.7)	19 (16.6)	12 (20.0)	8 (32.0)	12 (25.0)	0.36
No ECMO	7 (11.4)	3 (2.6)	5 (8.3)	3 (12.0)	3 (6.2)	0.15
Palliative care ^g	1 (1.6)	18 (16.5)	7 (12.2)	4 (16.6)	5 (10.8)	0.006

Data are n (%) or median (interquartile range)

HbA1c, glycated hemoglobin A1c; OAD, oral hypoglycemic agent; COPD, Chronic obstructive pulmonary disease; SAPS, Simplified Acute Physiology Score, 2 missing values (306 patients with data); RRT, renal replacement therapy; IMV, invasive mechanical ventilation; CPR, cardiopulmonary resuscitation

^aMissing data in 15 patients (293 patients with data)

^bMissing data in 2 patients (306 patients with data)

^cSystemic or inhalatory corticosteroids

^dImmunosuppressive therapy was defined as: treatment with Metotrexate, Azatioprin, Ciklosporin, Tracolimus, Infliximab

^eP values for the comparison between no chronic dysglycemia and chronic dysglycemia, Mann-Whitney U test was used for comparison of continuous data and Fischer's exact test for comparison of categorical data

^fDecision taken any time during ICU stay

^gDecision to go over to palliative care taken during ICU stay

1
2
3 Patients with chronic dysglycemia were older, were more likely to have hypertension,
4 malignancy and/or chronic kidney disease, and had higher SAPS 3 than patients
5 without chronic dysglycemia. Overall, 14 (22.9%) patients in the no chronic
6 dysglycemia group and 53 (21.5%) patients in the chronic dysglycemia group
7 received one or more limitations of life-supporting therapies during their ICU stay.
8 “No Cardiopulmonary resuscitation (CPR)” was the most common treatment
9 limitation. We observed the highest proportion of limitations among patients with
10 known (controlled or uncontrolled) diabetes. Decision to switch to palliative care was
11 made in 1 (1.6%) patient in the no chronic dysglycemia group and 34 (13.8%)
12 patients in the chronic dysglycemia group (P=0.006). Cumulative percentage of
13 treatment limitations relative ICU admission is displayed in Figures S1-S4.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 *Primary outcome*

31
32 In the nested cohort of 206 consecutive patients with available HbA1c, 169 (82.0%;
33 95% CI 76.1%-87.0%) were diagnosed with chronic dysglycemia. Prediabetes was
34 present in 83 (40.2%, 95% CI 33.5%-47.3%), unknown diabetes in 43 (20.9%, 95%
35 CI 15.5%-27.1%), well-controlled diabetes in 16 (7.8%, 95% CI 4.5%-12.3%), and
36 uncontrolled diabetes in 27 (13.1%, 95% CI 8.8%-18.5%) patients (Figure 2).
37
38
39
40
41
42
43
44
45
46

47 *Secondary outcomes*

48
49 Nine (14.7%) patients in the no chronic dysglycemia group and 62 (25.1%) patients
50 in the chronic dysglycemia group died within 90 days (P=0.09) (Table 2, Figure 3 and
51 Figure S5). ICU length of stay and duration of IMV were similar in the two groups.
52 IMV was delivered to 42 (68.8%) patients without chronic dysglycemia and to 187
53 (75.7%) patients with chronic dysglycemia (P=0.32). RRT was delivered to 17
54
55
56
57
58
59
60

(27.9%) no chronic dysglycemia patients and 42 (17.0%) chronic dysglycemia patients (P=0.06) (Table 2 and Table 3).

Table 2. Secondary outcomes

Outcomes	Chronic dysglycemia					P ^a
	No chronic dysglycemia (n = 61)	Prediabetes (n = 114)	Unknown diabetes (n = 60)	Controlled diabetes (n = 25)	Uncontrolled diabetes (n = 48)	
90-day mortality, n (%)	9 (14.7)	28 (24.5)	12 (20.0)	7 (28.0)	15 (31.2)	0.09
ICU length of stay, days	9 (4, 25)	14 (6, 24)	13 (6, 28)	8 (5, 21)	11 (7, 22)	0.69
Invasive mechanical ventilation, days	16 (8, 29)	14 (10, 23)	15 (10, 27)	15 (6, 21)	14 (9, 22)	0.60
Renal replacement therapy, n (%)	17 (27.9)	22 (19.3)	11 (18.3)	1 (4.0)	8 (16.6)	0.06

Data are n (%) or median (interquartile range)

ICU lengths of stay (4 missing values because of transfer to other hospital)

^aP values for the comparison between no chronic dysglycemia and chronic dysglycemia, Mann-Whitney U test was used for comparison of continuous data and Fischer's exact test for comparison of categorical data.

Table 3. Multivariable regression analyses showing the association of chronic dysglycemia (versus no chronic dysglycemia) with secondary outcomes

Outcome measure	No Chronic Dysglycemia	Chronic Dysglycemia	Adjusted Risk Estimate (95% CI) ^a	P ^a	Adjusted Risk Estimate (95% CI) ^b	P ^b	Statistical test
90-day mortality n (%)	9/61 (14.7)	62/247 (25.1)	1.61 (0.79 to 3.26)	0.18	1.54 (0.74 to 3.19)	0.24	Cox regression
ICU length of stay, days							
All patients	9 (4, 25)	13 (6, 23)	1.06 (0.78 to 1.43)	0.70	1.05 (0.77 to 1.44)	0.71	Linear regression
ICU survivors ^c	9 (5, 27)	14 (7, 24)	1.04 (0.76 to 1.43)	0.75	1.05 (0.76 to 1.44)	0.75	Linear regression
Invasive mechanical ventilation duration, days							
All patients ^d	16 (8, 29)	14 (10, 23)	0.92 (0.68 to 1.23)	0.58	0.93 (0.69 to 1.24)	0.63	Linear regression
ICU survivors ^e	16 (8, 30)	15 (10, 23)	0.93 (0.70 to 1.23)	0.61	0.92 (0.70 to 1.22)	0.59	Linear regression
Renal replacement therapy, n (%)							

All patients	17/61 (27.9)	42/247 (17.0)	0.52 (0.26 to 1.02)	0.06	0.49 (0.24 to 0.99)	0.04	Logistic regression
Patients without treatment limitation as no RRT	17/57 (29.8)	42/224 (18.8)	0.52 (0.26 to 1.04)	0.10	0.52 (0.25 to 1.07)	0.08	Logistic regression

^aMultivariable models were adjusted for Simplified Acute Physiology Score (SAPS) 3, age and sex.

^bMultivariable models were adjusted for Simplified Acute Physiology Score (SAPS) 3, age, sex, hypertension, any malignancy, any treatment limitation on admission and chronic corticosteroid use

^cICU length of stay in ICU survivors, 260 observations

^dInvasive mechanical ventilation duration, 227 observations

^eInvasive mechanical ventilation duration in ICU survivors, 189 observations

On multivariable regression analysis we observed a numerically higher mortality (adjusted HR 1.54, 95% CI 0.74-3.19, P=0.24) and significantly lower RRT use (adjusted OR 0.49, 95% CI 0.24-0.99, P=0.04) in patients with chronic dysglycemia (Table 3). No association with RRT was observed after exclusion of patients with “No RRT” as treatment limitation. In the post-hoc exploratory comparison between subgroups, RRT use was higher in the no diabetes group compared to the controlled diabetes group, as well as in the uncontrolled diabetes compared to controlled diabetes group (Table S1). Individuals with uncontrolled diabetes had the lowest probability of survival followed by individuals with controlled diabetes and prediabetes. The highest probability of survival was observed among patients with no chronic dysglycemia and prediabetes, respectively (Figure S5). However, we observed no statistically significant differences in mortality in the post-hoc comparison of subgroups (Table S1).

Discussions

Key findings

We performed a multicenter observational investigation to determine the prevalence of chronic dysglycemia and its impact on clinical outcomes among Covid-19 patients

1
2
3 admitted to ICU. Using available information about the patients' diabetic status in
4
5 combination with routine HbA1c assessment, we found that 82% had chronic
6
7 dysglycemia with two thirds having either prediabetes or undiagnosed diabetes. We
8
9 observed numerically higher 90-day mortality in patients with chronic dysglycemia,
10
11 with the highest mortality (31%) observed among those with uncontrolled diabetes.
12
13 Conversely, the proportion of patients receiving RRT was lower among patients with
14
15 chronic dysglycemia even when patients without "No RRT" as treatment limitation
16
17 were considered separately. We found no association of chronic dysglycemia with
18
19 ICU length of stay or duration of IMV.
20
21
22
23
24
25

26 *Relationship with previous studies*

27
28 A global meta-analysis of more than 16000 ICU patients with Covid-19 suggests a
29
30 pooled prevalence of known diabetes between 23-31% [13], close to the observed
31
32 prevalence in our study (21%). However, few studies have used additional HbA1c
33
34 measurements to assess the actual prevalence of chronic dysglycemia, including
35
36 prediabetes and undiagnosed diabetes. One such ICU study from Austria found a
37
38 prevalence of chronic dysglycemia of 85%, which is in close agreement with our
39
40 findings [14]. However, the Austrian study did not assess consecutive patients and
41
42 may therefore be prone to selection bias.
43
44
45

46
47 Our findings indicate that chronic dysglycemia is more common in Covid-19 patients
48
49 than in ICU patients with other admission diagnoses. In fact, in a pre-Covid-19 cohort
50
51 of general ICU patients we found a corresponding dysglycemia prevalence of 33%
52
53 [10]. The relationship between severe SARS-CoV-2 infection and dysglycemia has
54
55 different potential explanations. SARS-CoV-2 enters cells in various organs, including
56
57 the pancreas, via angiotensin-converting enzyme II (ACE2). As ACE2 is involved in
58
59
60

1
2
3 regulating pancreatic beta-cell function, a link between SARS-CoV-2 infection and
4 beta-cell dysfunction and diabetes development has been suggested [15].
5

6
7 Interestingly, the prevalence of elevated HbA1c below the diabetes diagnostic
8 threshold (prediabetes) was markedly higher in our Covid-19 cohort than in our
9 previous pre-Covid-19 cohort (40% vs 9%). It is possible that the duration of Covid-
10 19 symptoms before ICU admission (typically ten days in the literature [16]) was
11 sufficient to trigger new onset hyperglycemia with mildly elevated HbA1c.
12
13

14
15 In addition to the above speculations about SARS-CoV-2 as a *cause* of dysglycemia,
16 there is also evidence suggesting that patients with preexisting dysglycemia are
17 prone to a more severe course of Covid-19. For example, some studies have shown
18 that hospitalized SARS-CoV-2 positive with prediabetes, unknown diabetes, and
19 known poorly controlled diabetes are at increased risk of SARS-CoV-2 associated
20 respiratory failure requiring intensive care [17]. A higher burden of comorbidities,
21 hyperglycemia *per se*, and chronic low-grade inflammation in diabetes may explain
22 this observation [18].
23
24

25
26 Wang et al identifies fasting glucose as an independent predictor for 28-day mortality
27 in hospitalized individuals with Covid-19 and previously unknown diabetes. However,
28 HbA1c was not assessed and interference from stress hyperglycemia might have led
29 to the different results compared to our study [19].
30
31

32
33 Others [20], identified an increased risk of death in individuals with diabetes and
34 increasing levels of HbA1c above 48 mmol/mol and known diabetes in a large cohort
35 of hospitalized patients, but not in critically ill individuals.
36
37

38
39 Whether chronic dysglycemia is associated with worse outcomes among Covid-19
40 patients admitted to ICU remains uncertain. Dennis et al [21] found increased
41 mortality risk at 30 days (HR 1.23 [95% CI 1.14, 1.32]) compared to patients with no
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diabetes in patients admitted to the high Dependency Unit or ICU, but did not take
4
5 HbA1c into consideration. A multicenter study from France including 410 ICU
6
7 patients with Covid-19, found no association between the severity of dysglycemia
8
9 and tracheal intubation and/or death within 7 days of admission in patients with
10
11 diabetes than in those without diabetes [22]. This is in accordance with the findings of
12
13 our study. In contrast, others found higher mortality in the subgroup of mechanically
14
15 ventilated patients with diabetes [14].
16
17

18
19 We previously demonstrated an independent association between chronic
20
21 dysglycemia and need for RRT in critically ill non-Covid-19 patients [10]. This
22
23 association was, however, not found in the present study. In fact, we observed a
24
25 higher proportion of patients requiring RRT among our patients without chronic
26
27 dysglycemia and an inverse association between chronic dysglycemia and RRT use.
28
29 Only one individual in the controlled diabetes subgroup received RRT during ICU
30
31 stay. We believe this surprising finding may be due to treatment limitations. In fact,
32
33 after exclusion of patients with treatment limitation “not for RRT”, we observed no
34
35 statistically significant association between chronic dysglycemia and RRT use.
36
37
38 Limitations in life-sustaining care were more common in the known diabetes groups
39
40 (well controlled and uncontrolled diabetes) than in all other groups. We cannot
41
42 exclude the possibility that patients with severe acute or chronic kidney injury did not
43
44 reach the ICU because of treatment limitation decisions made at hospital arrival or on
45
46 the medical ward. This might have influenced the number of patients with kidney
47
48 injury reaching the ICU, affecting predominantly patients with chronic dysglycemia,
49
50 as they are usually older and have multiple comorbidities.
51
52
53
54
55
56
57

58 *Strengths and limitations*

59
60

1
2
3 Our study has several strengths. It is the first to assess the prevalence of chronic
4 dysglycemia in an ICU population with Covid-19 based on additional quantification of
5 admission HbA1c. This approach reduced bias due to events that would have
6 influenced HbA1c values obtained before ICU admission. We restricted the
7 prevalence assessment to a cohort of patients who were admitted to ICUs where
8 HbA1c was part of the routine laboratory panel, thereby reducing the risk of
9 ascertainment bias. Additionally, by measuring HbA1c in all patients admitted to the
10 ICU we identified 169 (82%) individuals with chronic dysglycemia and 86 (41.7%)
11 with diabetes. If HbA1c would not have been measured routinely at ICU admission,
12 we would only have identified 43 (20.9%) individuals with diabetes. Furthermore, we
13 considered treatment limitations in our analysis of clinical outcomes, thereby
14 reducing the risk of treatment selection bias. Finally, we included patients admitted to
15 ten ICUs in three University hospitals, thus providing a degree of external validity for
16 applying our findings to similar settings.

17
18 Our study has limitations. We lack data on conditions and treatment that might have
19 influenced admission HbA1c, such as haemoglobinopathies and blood transfusion
20 before ICU admission. Since interviews with patients or relatives were not performed,
21 a degree of misclassification due to non-documented dysglycemia diagnoses cannot
22 be ruled out. However, such interviews would have been logistically difficult during
23 the ongoing pandemic. We used an HbA1c cutoff of 42-47 mmol/mol (6.0-6.4%) to
24 classify prediabetes. If we instead had used the cutoff suggested by the ADA (39-47
25 mmol/mol [5.7-6.4%]), our prevalence of chronic dysglycemia would have increased
26 from 82.0% to 91.3%. This approach did not, however, alter the association with the
27 secondary outcomes (data not shown). In addition, we lack information about
28 glycemic control during intensive care, which might have modified clinical outcomes.

1
2
3 The observational nature of the study does not imply causation. Generalizability of
4 our results is limited to populations with similar health care systems and similar legal
5 frame-works for decisions on treatment limitations. Finally, the limited sample size
6 may limit the conclusion regarding secondary outcomes that can be drawn from the
7 data.
8
9
10
11
12
13
14
15
16

17 **Conclusion**

18
19 In our multicenter cohort of Covid-19 patients admitted to the ICU, HbA1c screening
20 diagnosed chronic dysglycemia in four out of five patients with the majority having
21 either prediabetes or previously undiagnosed diabetes. Chronic dysglycemia was not
22 significantly associated with mortality, ICU length of stay, duration of invasive
23 mechanical ventilation or renal replacement therapy use after considering treatment
24 limitations. These findings indicate that chronic dysglycemia may be a risk factor for
25 severe Covid-19. However, Covid-19 prognosis in the ICU does not appear to be
26 modified by chronic dysglycemia.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Author Contributions:**

42 AB, SR, MC, JG, AO, CS and JM contributed to the concept and design of the study.

43
44
45
46
47 AB, SR, CH and JM collected data.

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

AB and JM drafted the manuscript.

All authors critical reviewed and approved the final manuscript.

1
2
3 AB accepts full responsibility for the work and the conduct of the study, had access to
4
5 the data, and controlled the decision to publish.
6
7
8
9
10

11
12 **Funding** AB and JM were supported by Region Stockholm (clinical research
13
14 appointment and ALF project grants), grant number 580282.
15
16

17
18 A non-peer-reviewed version of this article has been a part of a publicly defended PhD
19
20 thesis ISBN 978-91-8016-719-2 and was submitted to Karolinska Institute Open
21
22 Archive, available at <https://openarchive.ki.se/xmlui/handle/10616/48203> on 19
23
24 [September 2022](#).
25
26

27
28 **Competing interest:** The authors have no competing interest relevant to this work.
29

30
31 **Data availability:** The data that support the findings of this study are available from
32
33 the corresponding author upon reasonable request.
34

35
36 **Ethics Approval Statement:** The study was approved by the Swedish Ethical
37
38 Review Authority (approval number 2020-01302).
39

40 41 **References**

- 42
43 [1] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities
44 and its effects in patients infected with SARS-CoV-2: a systematic review and meta-
45 analysis. *International Journal of Infectious Diseases* 2020;94:91-5.
46 doi:10.1016/j.ijid.2020.03.017
- 47 [2] Liu Y, Lu R, Wang J, Cheng Q, Zhang R, Zhang S, et al. Diabetes, even newly
48 defined by HbA1c testing, is associated with an increased risk of in-hospital death in
49 adults with COVID-19. *BMC Endocrine Disorders* 2021;21(1):1-10.
50 doi:10.1186/s12902-021-00717-6
- 51 [3] Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and
52 its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European*
53 *Respiratory Journal* 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
- 54 [4] Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection
55 are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol*
56 2020;127:104354. doi:10.1016/j.jcv.2020.104354
57
58
59
60

- 1
2
3 [5] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
4 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
5 study. *The Lancet* 2020;395. doi:10.1016/S0140-6736(20)30566-3
6
7 [6] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for
8 the progression and prognosis of COVID-19. *Diabetes/metabolism research and*
9 *reviews* 2020:e3319.
10
11 [7] Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J, et al. Clinical Features and Risk
12 Factors of ICU Admission for COVID-19 Patients with Diabetes. *Journal of Diabetes*
13 *Research* 2020;2020:5237840. doi:10.1155/2020/5237840
14
15 [8] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk
16 Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care
17 Units in Lombardy, Italy. *JAMA internal medicine* 2020;180(10):1345-55.
18 doi:10.1001/jamainternmed.2020.3539
19
20 [9] Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed
21 diabetes in adults. *Diabetes Research and Clinical Practice* 2014;103(2):150-60.
22 doi:https://doi.org/10.1016/j.diabres.2013.11.001
23
24 [10] Balintescu A, Palmgren I, Lipcsey M, Oldner A, Larsson A, Cronhjort M, et al.
25 Prevalence and impact of chronic dysglycemia in intensive care unit patients-A
26 retrospective cohort study. *Acta Anaesthesiol Scand* 2021;65(1):82-91.
27 doi:10.1111/aas.13695
28
29 [11] Erik von Elm DGA, Matthias Egger, Stuart J. Pocock, Peter C. Gøtzsche, and Jan P.
30 Vandenbroucke. The Strengthening the Reporting of Observational Studies in
31 Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies.
32 *Annals of Internal Medicine* 2007;147(8):573-7. doi:10.7326/0003-4819-147-8-
33 200710160-00010 %m 17938396
34
35 [12] Organisation WH. World Health Organisation. Use of Glycated Haemoglobin
36 (HbA1c) in the Diagnosis of Diabetes Mellitus,
37 [https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-\(-hba1c\)-in-](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(-hba1c)-in-diagnosis-of-diabetes-mellitus)
38 [diagnosis-of-diabetes-mellitus](https://www.who.int/publications/i/item/use-of-glycated-haemoglobin-(-hba1c)-in-diagnosis-of-diabetes-mellitus); [accessed 07 Fenruary 2022].
39
40 [13] Tan E, Song J, Deane AM, Plummer MP. Global Impact of Coronavirus Disease 2019
41 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis.
42 *Chest* 2021;159(2):524-36. doi:https://doi.org/10.1016/j.chest.2020.10.014
43
44 [14] Klein SJ, Mayerhöfer T, Fries D, Preuß Hernández C, Joannidis M, Collaborators, et
45 al. Elevated HbA1c remains a predominant finding in severe COVID-19 and may be
46 associated with increased mortality in patients requiring mechanical ventilation.
47 *Critical Care* 2021;25(1):1-4. doi:10.1186/s13054-021-03730-2
48
49 [15] Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for
50 relationship between SARS-CoV-2 and diabetes. *Acta Physiologica* 2021;233(4):1-13.
51 doi:10.1111/apha.13733
52
53 [16] Larsson E, Brattstrom O, Agvald-Ohman C, Grip J, Jalde FC, Stralin K, et al.
54 Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary
55 hospital in Stockholm, Sweden. *Acta anaesthesiologica Scandinavica* 2021;65(1):76-
56 81. doi:10.1111/aas.13694
57
58 [17] Rysz S, Jonsson Fagerlund M, Rimes-Stigare C, Larsson E, Campoccia Jalde F,
59 Mårtensson J. Chronic dysglycemia and risk of SARS-CoV-2 associated respiratory
60 failure in hospitalized patients. *Acta anaesthesiologica Scandinavica* 2022;66(1):48-
55. doi:10.1136/bjsports-2021-104080.
61
62 [18] Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the
63 Interrelationship and Risks for a Severe Course. *Frontiers in endocrinology*
64 2021;12:649525. doi:10.3389/fendo.2021.649525


- 1
2
3 [19] Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at
4 admission is an independent predictor for 28-day mortality in patients with COVID-19
5 without previous diagnosis of diabetes: a multi-centre retrospective study.
6 *Diabetologia* 2020;63(10):2102-11. doi:10.1007/s00125-020-05209-1
7
8 [20] Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for
9 COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a
10 population-based cohort study. *The lancet Diabetes & endocrinology* 2020;8(10):823-
11 33. doi:10.1016/S2213-8587(20)30271-0
12
13 [21] Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al.
14 Type 2 Diabetes and COVID-19-Related Mortality in the Critical Care Setting: A
15 National Cohort Study in England, March-July 2020. *Diabetes Care* 2021;44(1):50-7.
16 doi:10.2337/dc20-1444
17
18 [22] Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic
19 characteristics and prognosis of inpatients with COVID-19 and diabetes: the
20 CORONADO study. *Diabetologia* 2020;63(8):1500-15. doi:10.1007/s00125-020-
21 05180-x
22

Figure legends

23
24
25 **Figure 1.** Flow chart of study population

26
27 **Figure 2.** Prevalence of prediabetes, unknown diabetes and known diabetes among 206
28 consecutive ICU patients with Covid-19

29
30 **Figure 3.** Probability of survival in no chronic dysglycemia patients and in patients with
31 chronic dysglycemia
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Prevalence of prediabetes, unknown diabetes and known diabetes among 206 consecutive ICU patients with Covid-19

144x102mm (144 x 144 DPI)




Figure 3. Probability of survival in no chronic dysglycemia patients and in patients with chronic dysglycemi

770x521mm (144 x 144 DPI)

Table S1: Post-hoc exploratory comparison between the subgroups for 90 days mortality and Renal replacement therapy

Subgroups	90 day mortality		Renal replacement therapy	
	N (%)	p	N (%)	p
No chronic dysglycemia vs Prediabetes	9/61 (14.7) vs 28/114 (24.5)	0.17	17/61 (27.8) vs 22/114 (19.2)	0.25
No chronic dysglycemia vs Unknown diabetes	9/61 (14.7) vs 12/60 (20.0)	0.48	17/61 (27.8) vs 11/60 (18.3)	0.28
No chronic dysglycemia vs Controlled diabetes	9/61 (14.7) vs 7/25 (28.0)	0.22	17/61 (27.8) vs 1/25 (4.0)	0.01
No chronic dysglycemia vs Uncontrolled diabetes	9/61 (14.7) vs 15/48 (31.2)	0.06	17/61 (27.8) vs 8/48 (16.6)	0.25
Prediabetes vs Unknown diabetes	28/114 (24.5) vs 12/60 (20.0)	0.57	22/114 (19.2) vs 11/60 (18.3)	1
Prediabetes vs Controlled diabetes	28/114 (24.5) vs 7/25 (28.0)	0.79	22/114 (19.2) vs 1/25 (4.0)	0.07
Prediabetes vs Uncontrolled diabetes	28/114 (24.5) vs 15/48 (31.2)	0.43	22/114 (19.2) vs 8/48 (16.6)	0.8
Unknown diabetes vs Controlled diabetes	12/60 (20.0) vs 7/25 (28.0)	0.41	11/60 (18.3) vs 1/25 (4.0)	0.1
Unknown diabetes vs Uncontrolled diabetes	12/60 (20.0) vs 15/48 (31.2)	0.18	11/60 (18.3) vs 8/48 (16.6)	1
Controlled vs Uncontrolled diabetes	7/25 (28.0) vs 15/48 (31.2)	0.77	1/25 (4.0) vs 8/48 (16.6)	0.01
No chronic dysglycemia and prediabetes vs unknown and known diabetes	37/175 (21.1) vs 34/133 (25.5)	0.41	39/175 (22.2) vs 20/133 (15.0)	0.14

P values calculated with Fischer's exact test




Figure S1. Cumulative percentage of patients with a treatment limitation: no renal replacement therapy. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S2. Cumulative percentage of patients with a treatment limitation: no cardiopulmonary resuscitation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S3. Cumulative percentage of patients with a treatment limitation: no invasive mechanical ventilation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S4. Cumulative percentage of patients with a treatment limitation: no extracorporeal membrane oxygenation. Day 0 (zero) denotes the day of admission to the intensive care unit.




Figure S5. Probability of survival in the study groups

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Page references for document: **Chronic dysglycemia in critically ill patients with Covid-19 – a retrospective cohort study**

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods⁴			
Study design	4	Present key elements of study design early in the paper	4, 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5-7 NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5-6, Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 8 NA NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8-9, Figure 1 Figure 1 Figure 1

1	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
2				Table
3				1
4			(b) Indicate number of participants with missing data for each variable of interest	Table
5				1
6			(c) Summarise follow-up time (eg, average and total amount)	NA
7				
8	Outcome data	15*	Report numbers of outcome events or summary measures over time	10-11
9				Table
10				2-3

For peer review only

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 2 3 4 5 6 7 8	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10-11 Table 3
9 10 11 12	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11 Figure 2,3,S1- 4, S5
13	Discussion			
14	Key results	18	Summarise key results with reference to study objectives	11
15 16 17	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
18 19 20 21	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
22	Generalisability	21	Discuss the generalisability (external validity) of the study results	13-14
23	Other information			
24 25 26	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.